



About this report

TRANSPARENT REPORTING

This annual report reflects Grifols' commitment to transparency and ongoing efforts to enhance its financial and non-financial performance.

PREPARATION PRINCIPLES

STANDARDS

SUSTAINABILITY

STAKEHOLDER
INCLUSIVENESS

COMPREHENSIVENESS

MATERIALITY

CONTENT

- Financial Information
- Non-Financial Information: GRI, SASB, Law 11/2018, UN Global Compact principles and Sustainable Development Goals
- Methodologies: Total Tax Contribution, SROI and Gender Pay Gap

About this report

In its commitment to transparency and efficiency, Grifols prepared its Integrated and Sustainability Annual Report following the recommendations contained in “International Integrated Reporting Framework” of the International Integrated Reporting Council (IIRC).

This report, subject to independent review, presents group’s financial and non-financial information in compliance with current regulatory provisions¹.

This Integrated and Sustainability Annual Report is an exact copy of the Consolidated Non-Financial Information Statement. This report complies with the disclosure requirements for a Statement of Non-Financial Information (see Annex VI “Index of context required by Law 11/2018, of December 28, regarding non-financial information and diversity”), which offers an overview of the impact of Grifols’ activity on the employee pool, environmental and social issues, human rights, and the fight against corruption and bribery, including measures to promote the principles of equality and opportunity among men and women, non-discrimination, inclusion of people with disabilities and universal accessibility.

This report has been prepared in accordance with GRI standards as detailed in Annex VII “GRI Content Index.” Also included are SASB standards relating

to the “Biotechnology and Pharmaceuticals” sector, as per Annex VIII “SASB Content Index.”

Grifols’ efforts to promote the Sustainable Development Goals are outlined in Annex IX “Index of Grifols’ contribution to the SDGs and the principles of the United Nations Global Compact,” including information on priority SDGs and main contributions in 2023. In line with its formal adherence to the United Nations Global Compact, Grifols complies with the Communication on Progress (CoP) with this report.

This report describes the actions the company has taken and plans to take to implement the Global Compact Principles in the areas of human rights, labor, environment and anti-corruption, and their measurable outcomes. All measurable results are well described in each of the chapters of this report.

Unless stated to the contrary, the financial information presented in this report coincides with the Consolidated Financial Statements for the year ended December 31, 2023. It should be read jointly with the 2023 Consolidated Financial Statements, which have been subject to an external audit. Some financial indicators and ratios are classified as Alternative Performance Metrics (APMs) in accordance with European Securities Markets Authority (ESMA) guidelines.

Bases for the preparation of the Non-Financial Information Statement

In accordance with Law 11/2018 of December 28 on non-financial information and diversity, the Board of Directors of Grifols, S.A. (Grifols hereinafter) prepares the Non-Financial Information Statement for the fiscal year 2023 as a separate document and an integral part of the Consolidated Directors’ Report and as a separate document from the consolidated annual accounts. This report is publicly available on Grifols’ corporate website at www.grifols.com. This Integrated and Sustainability Annual Report is an exact copy of the Consolidated Non-Financial Information Statement.

Grifols analyzed the materiality of the requirements by Law 11/2018 while considering the opinion of its main stakeholders. As shown in Annex VI, “Index of the contents required by Law 11/2018, of December 28,” the Non-Financial Information Statement was prepared in accordance with the Global Reporting Initiative (GRI) Standards selected for requirements considered material to the business.

1. Among others, the Commercial Code, Consolidated Text of the Capital Companies Act and Law 11/2018, of December 28, which amends the Commercial Code, Consolidated Text of the Capital Companies Act and Accounts Auditing Act with regard to non-financial information and diversity, and which transposes Directive 2014/95/EU into Spanish law with regard to the disclosure of non-financial information.

Principles

This report was prepared in accordance with GRI standards:

Stakeholder inclusiveness: Grifols maintains an ongoing dialogue with its stakeholders. The group is able to effectively address their expectations and interests by anticipating their needs.

Context of sustainability: Grifols aspire to contribute to economic, environmental and social progress on local, regional and global levels. Its 2023 performance is contextualized within its countries of operation.

Materiality: This report features the corporate issues that have exerted the greatest economic, environmental and social impact, as well as those that could significantly shape stakeholder decisions and evaluations.

Comprehensiveness: The topics highlighted in this report adequately reflect the Group's most significant social, economic and environmental impacts, allowing stakeholders to assess their effectiveness in the 2023 fiscal year.

Scope of this report

This report covers the period from January 1st to December 31st, 2023, corresponding to Grifols' fiscal year.

For the purpose of this report, Grifols S.A. and all its subsidiaries are considered as "Grifols." The reported information includes all dependent companies with a stake greater than 51% or under control according to the IFRS definition as reflected in the Consolidated Financial Statements. A list of Grifols' subsidiaries can be found in Appendix I of the Consolidated Financial Statements for the annual period ending on December 31, 2023.

Regarding the information reported on Biotest, performance data for this company, particularly related to human resources and the environment, is presented in separate tables to allow comparability with previous years' information. Within the tables titled Grifols, the commercial subsidiaries acquired 100% in 2023 are: Biotest France SAS, Biotest UK Ltd., Biotest Italy S.r.l., Biotest Farmaceutica Ltda., Biotest Medical S.L.U.. The data for 2022 corresponds to the period from May to December 2022, unless otherwise indicated. The data for this company in 2023 covers the entire year, from January 1st to December 31st, 2023. Biotest annually publishes its management approaches and key policies at www.biotest.com.

The scope of this report includes all Grifols operations, from procurement (including plasma collection) and manufacturing to commercial subsidiaries.

In the sections where historical data appears, figures for the last three years (2021-2023) have been included where available.

The historical data presented in this report has not been recalculated to adjust for changes in the perimeter that occurred in each exercise. The only exception stems from the company's reorganization starting in 2022, by which business units do not correspond to the divisions delineated in previous reports, as captured in the following table. In cases where information is reported by unit, historical data was recalculated in 2022.

The financial information included in this report is derived from the Consolidated Financial Statements for the year ended December 31, 2023.

Business units from 2022 onward	Correspondence with former divisions
Plasma Procurement	Bioscience
Biopharma	Diagnostic
Diagnostic	Bio Supplies
Bio Supplies	Hospital y others
Others	

Limitations of the scope

Grifols believes that this report provides a reasonable and balanced reflection of its economic, environmental and social performance since the aforementioned exceptions do not significantly alter the consolidated indicators and in turn, do not affect readers' assessment of its results.

- Due to the complexity and global distribution of Grifols' activities, the scope of some quantitative indicators differs from the established standard, the scope being greater than 95% of turnover or employees in all cases.

“Environmental” chapter:

- The data provided in this section represents Grifols' total production and commercial activities with the exception of commercial subsidiaries with fewer than 10 employees.
- As most of Grifols' manufacturing facilities are located in the United States and Spain, the environmental information included in this section is classified by division and region as U.S., Spain and rest of the world (RoW).
- In 2023, the internal organization of Grifols plasma centers was altered: variations in the Bio Supplies business unit are due to the incorporation of IBBI blood donation centers, previously considered part of Biopharma. In 2023, the plasma donation centers became part of Biopharma, while the blood donation centers became part of the Bio Supplies unit. It also consolidated Access Biologicals for the entire year of 2023, whereas in 2022 it was only consolidated for six months.
- In 2023, the commercial subsidiaries in Argentina and Malaysia were not included as their workforces had fewer than 10 employees.
- In 2023, new data-collection software was implemented in all Grifols sites. Unlike the previous software, the new system does not allow the option of allocating a center to multiple business units, which affects how the “sales per business unit” metric is calculated for Grifols commercial subsidiaries. For this reason, the company created a dedicated unit for commercial subsidiaries, with no relative data by production or sales applied to them.

“Social” chapter:

- Grifols has included figures for the last two years classified by gender (female, male, non-binary and not declared), age and region (U.S., Europe and RoW) in all cases where historical figures were available. Europe includes Czech Republic, France, Germany, Ireland, Italy, Poland, Portugal, Spain, Sweden, Switzerland and United Kingdom.
- The scope of the indicators related to remuneration includes the workforce in Spain, Germany, U.S., Ireland, Italy, Poland, Portugal, Sweden, Switzerland and the United Kingdom.
- The data provided regarding training hours includes all group companies except Medion Grifols Diagnostic, AG, Araclon Biotech, S.L., Goetech, LLC, Grifols Diagnostic, AG, Araclon Biotech, S.L., Goetech, LLC, Grifols Worldwide Operations USA, Inc, Alkahest, Inc, Grifols Inn and New Technologies Limited, Plasmavita Healthcare GmbH, Plasmavita Healthcare II GmbH, GigaGen Inc and Grifols Canada Therapeutics, Inc. The data included represents 97.2% of Grifols global workforce as of December 31, 2023.
- Indicators for absenteeism, people with disabilities and accident rates are limited to data from the United States, Spain, Ireland and Germany.

The indicators included in this report have been compiled by Grifols. Sygris, a systematized reporting tool implemented in 2022, has enhanced its methodological rigor in comparison to previous years.

Subsequent events

Gotham City Research Report

On 9 January 2024, a short seller investor issued a report based on speculation and false information regarding Grifols' accounting and financial information. Although the company's fundamentals remain sound and unchanged and all financial information was duly reported in the audited financial statements, this action had a significant impact on Grifols' share price and corporate reputation.

The company is currently working to restore the confidence of markets, shareholders and other stakeholders in six key areas:

- Communication and collaboration with the Spanish regulator (CNMV).
- Transparent communication with all our stakeholders: sharing our clear response to the published report through live conference calls and multiple official communications on the company's website and on the CNMV portal. All press releases are publicly available on Grifols' website
- Clear and transparent communication with our teams and employee representatives, including major unions.
- Reinforced communication with investors, official communications, direct phone calls, video calls and e-mails.
- The company filed a complaint in the United States District Court for the Southern District of New York against Daniel Yu, Gotham City Research LLC, General Industrial Partners LLP, Cyrus de Weck, and their affiliates to claim for the financial and reputational damages caused to Grifols and their stakeholders as a result of the defendants' actions.
- The company established a dedicated working group comprising senior managers from the legal, communications, finance, investor relations and management teams, together with external advisors with expertise in communications.

As a result of the information published by Gotham City Research LLC, in relation to the accounting and financial information of Grifols, S.A. and subsidiaries, the National Securities Market Commission (CNMV), in the exercise of its supervisory powers, has made various requests for information to the Group. The Parent Company has responded to the requirements received, although at the date of preparation of these consolidated financial statements, the supervisory process has not been concluded.



All announcements are publicly available on our website
(<https://www.grifols.com/en/other-relevant-information>).

SRAAS Share Purchase Agreement

As indicated in note 12 of Consolidated Annual Accounts, Grifols and Haier Group Corporation ("Haier") entered into a Strategic Alliance and Share Purchase Agreement agreement to transfer the 20% shareholding in Shanghai RAAS Blood Products Co., Ltd. to Haier. On 29 February 2024, the period contractually established by the parties in relation to the completion of Haier's confirmatory due diligence has been satisfactorily concluded. Accordingly, the closing of the transaction is subject to obtaining pending ordinary regulatory approvals and the transaction is expected to close during the first half of 2024.

Annex I.

Bases for the preparation: scope and methodology – Total Tax Contribution

Purpose and scope

The “Fiscal Contribution” section included in the “Financial Performance” chapter provides information on the taxes paid by the Grifols Group globally in 2023 in a clear and concise manner. Disclosures includes data from the following territories: Spain, the United States, Ireland, Germany and United Kingdom, as the most relevant in terms of their business volume and presence within the Grifols Group.

The measurement used data obtained from information systems following the PwC Total Tax Contribution (TTC) methodology. In addition to the amounts indicated, other tax payments may have been omitted because they are not individually identified in the information systems and/or are not significant in terms of materiality.

TTC methodology

The Total Tax Contribution methodology measures the total impact of a company's tax payments. This assessment is made from the perspective of total tax contributions paid directly to the different public administrations as a result of the Grifols Group's economic activity.

In general, the TTC methodology allocates both input and output taxes to each tax year on a cash basis.

The following points should be kept in mind regarding this methodology:

1. It distinguishes between taxes that are a cost to Grifols and taxes collected.

Taxes borne are taxes paid by Grifols to the governments of countries in which it operates. These taxes represent an effective cost for Grifols, such as taxes on profits and certain environmental taxes.

The taxes collected are those that have been received as a result of Grifols' economic activity, without representing a cost to the Group other than that of its management. These include withholdings from workers due to income tax, VAT, and other taxes on products and services. Nonetheless, these amounts are paid into public coffers as a result of Grifols' economic activity and therefore should be included in the analysis since they represent tax revenue stemming from Grifols' operations.

2. TTC framework classifies taxes under 5 categories for clarification purposes:

(i) Profit taxes: taxes borne on profits earned by companies such as corporate income tax, business tax and taxes levied as withholding taxes on payments to third parties.

(ii) Property taxes: taxes on the ownership, sale, transfer or occupancy of property.

(iii) People (or Employment Taxes): employment-related taxes both borne and collected, including employee income tax withholdings and social security payments payable by both Grifols and the employee.

(iv) Taxes on Products and Services: indirect taxes on the production and consumption of goods and services, including VAT and customs duties.

(v) Planet (Environmental Taxes): taxes on the supply, use or consumption of products and services deemed to affect the environment.



3. It includes all tax payments made to public administrations

Readers should take into account that figures detailed in this report include tax payments made to public administrations for items whose characteristics make them tax-related, although they have not been classified as such for cyclical or historical reasons. Readers should also take into consideration that figures in this report exclude other amounts that, based on the methodology and reports issued by the OECD and other international administrations, are not considered a tax contribution.¹

4. Profit before taxes assumptions made during the preparation of this report

The amount of profit before tax excludes intercompany dividends to avoid duplicating the same income of various entities in the case of its distribution as dividends to other Grifols entities. This calculation enables reflecting the objective amount of profit before taxes at country levels and calculating the objective ETRs, as dividends are usually subject to beneficial tax treatment compared to the other types of income (i.e. “participation exemption” regime).

5. There are certain particularities with regard to value added tax (VAT) and equivalent taxes

Value added tax (and equivalent taxes) is characterized as a tax on products and services collected, the amount of which reflects the result of net payments made by Grifols to the tax authorities in its jurisdictions of operation in the corresponding period.

In calculating VAT, the country-specific figure indicated for this concept includes the positive amount paid to the corresponding tax authorities, resulting from subtracting the VAT accrued from the amount of VAT deducted.

No figure shall be shown for this item in cases in which the net amount resulting from subtracting VAT accrued from VAT deducted for an entire year and country is negative due to a refund.

On the other hand, VAT amounts that are not refundable because the value chain cannot be continued by means of the reverse charge instrument shall be considered as input tax on products and services, since they represent a cost for the company.

1. Main sources of Total Tax Contribution Methodology:



- <https://www.oecd.org/tax/tax-policy/oecd-classification-taxes-interpretative-guide.pdf>
- <http://www.ifs.org.uk/mirrleesReview/design>

Annex II.

SROI – Social Return on Investment (SROI) methodology

The Social Return on Investment (SROI) method aims to gain a deeper understanding of an organization's social, environmental and economic impact. The SROI method represents a valuable cost-benefit analysis, offering the leadership team and investors a solid decision-making tool to assess and optimize the firm's social and environmental impacts.

The SROI uses individual assessments to measure the change in stakeholders' lives because of Grifols' activities. The evaluations are quantified and recorded on an impact map, and monetary value is then assigned to the resulting social, environmental and economic impacts.

2023 global SROI analysis

The study was conducted by Hugo Narrillos Roux, holder of a doctorate with honors in economics from the Complutense University of Madrid, a specialist in social value and the author of "Social Economy: Valuation and Measurement of Social Investment (SROI method) and his doctoral thesis, "The Social Return on Investment: A Good Method to Measure the Social Value Created by Companies."

Mr. Narrillos Roux is recognized as an accredited SROI professional by Social Value International, a network of professionals dedicated to generating knowledge on change and social value. He serves as a faculty member at several universities and a social-impact consultant at leading global organizations.

Main references:

Alpha 1: Chapman, K.R., Stockley, R.A., Dawkins, C., Wilkes, M. M., Navickis, R. J. Augmentation therapy for α 1 antitrypsin deficiency: A meta-analysis. COPD: Journal of Chronic Obstructive Pulmonary Disease, 6:177-184 (2009).

Factor VIII: Pasi, J., Hermans, C., Hakimi, Z., Nazir, J., Aballéa, S., Ezzalfani, M., and Fatoye, F. (2022): Improvement in pain-related quality of life in patients with hemophilia A treated with rFVIII-Fc individualized prophylaxis: post hoc analysis from the A-LONG study. Therapeutic Advances in Hematology. 2022, Vol. 13: 1-9.

PID: The impact of plasma-derived therapies in Europe. The health and economic case for ensuring sustainable supply. Copenhagen Economics. June 2021. Available at: <https://www.copenhageneconomics.com/publications/publication/the-impact-of-plasma-derived-therapies-in-europe> (website visited on January, 2023).

SID: Benbrahim, O., Viillard, J. F., Choquet, S., Royer, B., Bauduer, F., Decaux, O., ... Lévy, V. (2018). The use of octagam and gammanorm in immunodeficiency associated with hematological malignancies: a prospective study from 21 French hematology departments. Hematology, 24(1), 173–182.

ITP: Ruqayyah J. Almizraq1, Donald R. Branch. Efficacy and mechanism of intravenous immunoglobulin treatment for immune thrombocytopenia in adults. Annals of Blood. Vol. 6 (March 2021).

GBS: Panagiotis, Z., Liampas, A., Pozotou, T., Parperis, K., Artemiadis, A., Hadjigeorgiou, G. Immunoglobulin use for the management of painful peripheral neuropathy: A systematic review and meta-analysis. (2022). Pain and Therapy (2022). 11:1219–1227

MG: Porras L.D., Homedes C., Alberti M.A., Santamaria V.V., Casasnovas C. (2022). Quality of life in myasthenia gravis and correlation of mg-qol15 with other functional scales. Journal of Clinical Medicine. 2022; 11(8).

HC: Runken, M. C., Caraceni, P., Fernandez, J., Zipprich, A., Carlton, R., & Bunke, M. (2019). The cost-effectiveness of albumin in the treatment of decompensated cirrhosis in Germany, Italy, and Spain. Health Economics Review, 9(1).

Annex III.

Methodology and calculation of the adjusted and unadjusted pay gap

The following groups have been excluded from the calculation:

- SELT
- Executive Chairperson
- Partial retirees
- Expatriates or displaced employees
- Employees of foundations
- Undeclared and non-binary employees
- The company Plasmavita Healthcare is not yet fully integrated into the systems and policies of Grifols at 100%.

In total, 19.660 employees have been included in the wage gap calculation, distributed by country as follows:

- United States: 13.852
- Spain: 4.103
- Germany: 1.334
- Ireland: 371

According to the Global Reporting Initiative standards, the unadjusted gender pay gap is the difference between the average salary of men and the average salary of women, calculated based on the average salary of men. For the purposes of this report, average salary is understood as the mean of the gross annual fixed salary at 100% employment.

$$\text{Brecha salarial} = \frac{(\text{Remuneración promedio hombres} - \text{Remuneración promedio mujeres})}{\text{Remuneración promedio hombres}}$$

Unlike the unadjusted gender pay gap, adjusted wage gaps allow isolating the effect of wages from existing differences between men and women, considering both their socio-economic characteristics (age, seniority, level of education, etc.) and the positions they hold (working hours, type of occupation, etc.). In this way, adjusted wage gaps serve as a more reliable indicator to measure whether men and women receive "equal pay for equal work".

The existence of an unadjusted gender pay gap does not directly imply gender-based discrimination, as various factors affecting the compensation for a specific position must be considered, such as required experience, tenure in the role, responsibility, supervisory roles, shift work, and hardship, among others.

Therefore, the adjusted wage gap has been estimated using a multiple linear regression model that quantifies, through a single equation, the relationship between predictor or independent variables ($X_{11}, X_{12}, \dots, X_{1M}$) and the dependent or response variable (W_i). This is done to better understand or explain the mechanisms of this relationship.

In this equation, W_i represents the gross annual fixed salary at 100% employment for employee i transformed to its logarithm, while Gender is a dichotomous variable equal to 1 if male and 0 if female.

$$\ln(W_i) = \beta_0 + \beta_1 * \text{Sexo}_i + \sum_{j=2}^M \beta_j * X_{ij} + \mu_i$$

The econometric calculation of the adjusted wage gap has taken into account the following variables: Age, seniority, area, business division, professional category, performance rating, level of education, type of contract, Geodif, Plasma or non-plasma.

The results are presented for each country separately to avoid applying a currency exchange rate that may distort the outcome.

Due to confidentiality and personal data protection reasons, wage gap data is not shown for professional categories where there are fewer than 4 individuals of each gender.

In some cases with small groups, the adjusted wage gap data is not shown as it is not possible to obtain statistically significant results through the econometric model. For these cases, only the unadjusted wage gap data is presented.

Annex IV.

Alliances and associations

- AECOC: Spanish Association of Manufacturers and Distributors
- AENE: Spanish Association of Manufacturers and Distributors of Enteral Nutrition Products
- AmCham: American Chamber of Commerce in Spain, China and Thailand
- ASEBIO: Spanish Association of Bio Companies
- BIOcom Life Sciences Organization of California: California association of bioscience companies and research institutes
- Biotechnology Innovation Organization (BIO): the world's premier biotech trade association whose membership includes industry firms, academic institutions and U.S. state-level centers and organizations
- CAEME: Argentine Association for Pharmaceutical and Biotech Products
- CBDL: Brazilian Chamber of In Vitro Diagnostics Companies
- EMIG: Ethical Medicines Industry Group
- EUCOPE: trade association representing small- to medium-sized pharmaceutical and med-tech firms in Europe
- EURORDIS: non-governmental patient-driven alliance representing 949 rare disease patient organizations in 73 countries
- Farmafluid: Spanish Association of Fluid Therapy and Parenteral Nutrition Pharmaceutical Laboratories
- Farmaindustria: Italian Association of Pharmaceutical Companies
- Global Business Alliance: an association of globally focused U.S. firms that promotes foreign investment in the country
- JACRI: Japanese Association of Clinical Reagents Industry
- LEEM: French industry association representing drug companies operating in France
- MedTech Europe: Trade association representing the medical technology industries, manufacturers of in vitro diagnostics and medical devices operating in Europe and diverse national associations
- National Health Council (U.S.): platform for diverse organizations to forge consensus and drive patient-centered health policy
- North Carolina BIO: trade association for North Carolina's life science industry whose membership includes companies and research institutions working in the pharmaceutical, medical device, diagnostic, clinical research and agricultural biotechnology sectors
- Pathology Technology Australia: Australian association of manufacturers and distributors of in vitro diagnostic reagents and systems.
- PPTA: Plasma Protein Therapeutics Association
- SIGRE: not-for-profit organization established to ensure proper environmental management of medicines and their packaging in the home
- SINDUSFARMA: Brazilian Association of Pharmaceutical Companies
- United States-Spain Council: An organization of U.S. and Spanish leaders who work to cultivate stronger ties between both countries

Grifols advances social progress by collaborating with an array of public- and private-sector organizations. The following table outlines its most significant financial contributions by industry:

Activity	Involvement / commitment	2023 contribution
PLASMA INDUSTRY	Grifols supports various projects related to the plasma industry, including the joint promotion of a global code of conduct, educational campaigns, access to clinical treatments, procurement of plasma as a raw material, and awareness campaigns on rare diseases.	2.136.677 €
PHARMACEUTICAL INDUSTRY	Defense of policies and practices to promote the discovery of and access to life-enhancing medicines and vaccines for people around the world. Efforts to reinforce regulatory systems to ensure maximum safety throughout the value chain, from production to patient administration while acting ethically and professionally in alignment with Grifols Codes of Conduct. ⁽¹⁾	236.517 €
MED-TECH INDUSTRY	Efforts to highlight the social value and contribution of medical technologies, facilitating their access to patients, healthcare professionals, operators and healthcare systems. Promotion of value-based innovation to create more sustainable healthcare systems and meet the growing needs and expectations of health and medical-care systems. Adherence to the highest ethical standards for all training initiatives and interactions with healthcare professionals. ⁽²⁾	103.565 €
BIOTECHNOLOGY INDUSTRY	Participation in national non-profit associations of several bio-tech firms, aimed at increasing their social awareness and promoting innovation by advocating for public policies that favor the growth of this essential industry. ⁽³⁾	161.889 €

(1) IFPMA - Homepage: (<https://www.ifpma.org/>)

(2) Medtech Europe – Homepage (<https://www.medtecheurope.org/>)

(3) ICBA – Homepage (<https://internationalbiotech.org/about/>)

Annex V.

Environmentally Sustainable Activities. Grifols' activities under European Taxonomy

European Union Taxonomy

One of the cornerstones of the European Union's Sustainable Finance Action Plan (SFAP) consisted of approving the EU Regulation 2020/852¹ (known as the Taxonomy Regulation) in 2020. European Taxonomy comprises a classification system devised by the European Union to evaluate whether an economic activity can be considered environmentally sustainable, thereby guiding the degree of environmental sustainability of an investment. Fundamentally, European Taxonomy aims to establish a common and transparent framework for companies and investors to assess and report the environmental impact of their business activities. Its overarching goal is to channel investments towards sustainable activities and support the shift towards a more sustainable, greener economy.

The Taxonomy addresses different economic activities and industries providing uniform criteria to evaluate their contribution toward six defined environmental objectives:

- Climate change mitigation
- Climate change adaptation
- Sustainable use and protection of water and marine resources
- Transition to a circular economy
- Pollution prevention and control
- Protection and restoration of biodiversity and ecosystems

These environmental objectives defined by the European Union are detailed in the Delegated Regulation (EU) 2021/2139² published on June 4, 2021. This regulation includes a comprehensive list of economic activities deemed environmentally sustainable. For each activity, the regulation provides a description and specifies the technical criteria required to determine whether it contributes significantly to any of the six environmental objectives. Additionally, it outlines the criteria to ensure that the activity is carried out in such a way that it does not harm any other environmental objectives. Furthermore, in order to align with the European Taxonomy and be considered as sustainable, organizations must adhere to minimum social safeguards.

¹ Regulation (EU) 2020/852 of the European Parliament and of the Council

² Commission Delegated Regulation (EU) 2021/2139 of 4 June 2021 supplementing Regulation (EU) 2020/852 of the European Parliament and of the Council and establishing the technical selection criteria to determine the conditions under which an economic activity is deemed to make a substantial contribution to climate change mitigation or adaptation, and to determine whether that economic activity causes significant harm to any of the other environmental objectives (europa.eu)

The European Taxonomy has established three key indicators based on specific financial ratios derived from data on CapEx investments, OpEx operating expenses and turnover linked to the activity carried out by the company³.

In this context, Grifols performed a comprehensive analysis of its economic activities along these three dimensions and their intersection with its six environmental objectives in order to determine which actions make a substantial contribution. The results were as follows:

	Turnover	CapEx	OpEx
Eligibility in figures (€)	5.096.622.614,77	132.070.212,93	45.300.275,21
% Eligibility	83,14%	82,42%	24,83%
Alignment in figures (€)	0	12.760,39	0
% Alignment	0%	0,008%	0%

This analysis was conducted in two phases: The first identified whether any of the economic activities associated with the three KPIs correspond to any of the activities outlined in the Taxonomy (eligibility assessment). The second assessed the extent to which these activities align with environmentally sustainable criteria (alignment).

First phase: Eligibility Analysis

This first phase involved assessing Grifols' economic indicators (CapEx, OpEx and turnover) to identify whether the company's activities correspond to the economic activities described in the Taxonomy Regulation on environmental objectives.

Unlike the previous two years, when the Taxonomy analysis was conducted solely in relation to the first two environmental objectives in which Grifols only reported activities linked to its investments or expenses incurred, this year marks a significant change. Grifols' primary activity, and part of the company's income, are included in the list of activities recognized by the Taxonomy. Specifically, this is "1.2. Manufacture of pharmaceuticals," which falls under the environmental objective "Pollution Prevention and Control."

³ The Taxonomy Regulation sets out specific criteria for using figures related to CapEx, and turnover, which diverge from traditional accounting concepts. Therefore, there may be discrepancies between the figures used to calculate the Taxonomy and those presented in other sections of Grifols' report.

Additionally, some of the company's other economic activities have been identified, which while not directly related to its main activity, are related to the investments or expenses incurred, and considered eligible under the Taxonomy.

List of Grifols' eligible activities for 2023

Objective	Activity	Brief description in accordance to the Regulation	Brief description in accordance to Grifols' activities
Pollution prevention and control	1.2 Manufacture of pharmaceuticals	Manufacture of pharmaceuticals	Grifols main activity, which consists of researching, developing, producing and marketing plasma-derived medicines and other innovative solutions.
Biodiversity	1.1 Conservation, including restoration, of habitats, ecosystems and species	Initiation, development and realisation on own account or on a fee or contract basis, of conservation activities, including restoration activities, aimed at maintaining or improving the status and trends of terrestrial, freshwater and marine habitats, ecosystems and populations of related fauna and flora species.	In the town of Clayton, USA, Grifols has more than 120 hectares of protected forest, located in the vicinity of Grifols' production facilities. This environment includes eight hiking trails and have more than 300 species of plants and animals. The main objective of this project is to protect a large area of forest as a habitat for wildlife.
Climate Change Mitigation	7.3 Installation, maintenance and repair of energy-efficient equipment	Individual renovation measures to install, maintain or repair energy-efficient equipment.	As part of Grifols' energy saving programme, the Erfurt donation centre has switched from conventional lighting to LED lighting. In addition, as a contribution to the objectives of Grifols' Sustainability Commitment, the Haema AG donation centre in Germany has installed a green roof covering which mainly provides greater energy savings and thermal insulation.
	7.4 Installation, maintenance and repair of charging stations for electric vehicles in buildings (and in parking spaces adjacent to buildings)	Installation, maintenance and repair of charging stations for electric vehicles in buildings and in parking spaces adjacent to buildings.	Grifols facilitates and promotes more sustainable mobility solutions by providing infrastructure for electric vehicle charging in the car parks of Grifols employees at the Sant Cugat offices. This year, all the electric vehicle chargers located in underground car parks have been relocated to outdoor parking areas.

Second phase: Alignment Analysis

In line with the requirements set out in the Taxonomy Regulation for the 2023 fiscal year, Grifols' analysis specifically focused on those activities that contribute to the first two environmental objectives: Climate Change Mitigation and Climate Change Adaptation. This assessment was carried out based on the three essential conditions that an economic activity must satisfy to be classified as environmentally sustainable:

- Offer substantial contribution to at least one of the 6 objectives defined by the Taxonomy. (EU Regulation 2020/852 Arts. 10 to 16)
- Do no significant harm to the other defined objectives. (EU Regulation 2020/852 Art. 17)
- Comply with minimum social safeguards (EU Regulation 2020/852 Art. 18)

The results of the alignment analysis determine that Grifols contributes via investments to the objective of Climate Change mitigation. The following activities are considered to be classifiable as environmentally sustainable:

- 7.4 Installation, maintenance and repair of electric vehicle charging stations in buildings (and parking spaces adjacent to buildings).

In the alignment analysis of Grifols' economic activities for the 2023 fiscal year, the aforementioned activities are deemed environmentally sustainable based on their substantial contribution to the "climate change mitigation" objective. These activities meet the technical criteria for substantial contribution and adhere to the principle of Do Not Significant Harm (DNSH) to other environmental objectives defined in the European Taxonomy. Additionally, they comply with the minimum social safeguards. The ways in which these activities meet each of the three conditions are detailed below:

Technical criteria for substantial contribution to climate change mitigation

Grifols is considered to contribute to the Climate Change Mitigation objective in the following economic activities, 7.4 Installation, maintenance and repair of charging stations for electric vehicles in buildings, since these activities meet the technical criteria of substantial contribution to the environmental objectives.

Do No Significant Harm (DNSH)

Parallel to this, in the "Environment" section of this document, it was determined that Grifols' economic activities adhere to the "Do No Significant Harm" technical criteria. Specifically, for these activities, the only criterion to be analyzed comes under the "Climate Change Adaptation" objective, as the regulation itself states that no significant harm must be caused to any of the other four objectives.

3.3. Minimum Social Safeguards

Finally, these activities are considered to be in alignment with environmentally sustainable criteria, since the sections on "Promoting Integrity" and "Human Rights" in this document determine that Grifols complies with the "Minimum Social Safeguards" set out in Article 18 of the Taxonomy Regulation.

Calculation of Economic Indicators

To illustrate Grifols' contribution to sustainability, the following shows the percentages representing the proportion of the company's total turnover, CapEx and OpEx which are attributable to eligible and/or aligned activities. This offers a transparent view of how much of the company's financial activities contribute to sustainability.

Turnover percentage calculation

The value of the turnover percentage, as set out in Article 8(2)(a) of EU Regulation 2020/852, was calculated by taking the portion of the net turnover attributable to products or services, including intangible assets. This portion is associated with economic activities that comply with the taxonomy and represent the numerator in the calculation, divided by the net turnover (denominator) as defined in Article 2(5) of Directive 2013/34/EU.

Turnover includes revenue recognized in accordance with International Accounting Standard (IAS) 1, paragraph 82, letter a), adopted by Commission Regulation (EC) No. 1126/2008. In the specific case of Grifols, the numerator in the turnover KPI is calculated as the total turnover (recorded under Group 70 of the General Chart of Accounts) selected based on accounts considered eligible from a taxonomic standpoint. With regard to the numerator of the turnover KPI, Grifols identified "Activity 1.2: Manufacture of pharmaceuticals" as eligible. This corresponds to environmental objective "Pollution Prevention and Control." Consequently, revenues from the Biopharma functional area have been included in the numerator calculation.

The denominator corresponds to Grifols' total turnover.

CapEx percentage calculation

The CapEx ratio, as stipulated in Article 8(2)(b) of Regulation (EU) 2020/852, was calculated as the numerator divided by the denominator, the denominator being the additions to tangible and intangible assets during the reporting period before depreciation, amortization and possible revaluations, including those resulting from revaluations and impairments during the relevant period, excluding changes in fair value. The denominator also includes additions to tangible and intangible assets resulting from business combinations.

Specifically, the denominator is Grifols' total CapEx, which includes investments in intangible assets, investments in property, plant and equipment, investments in assets for rights of use and assets transferred without consideration. The numerator consists solely of the aggregation of the CapEx of the activities considered eligible from a taxonomic standpoint.

OpEx percentage calculation

The OpEx ratio, according to Article 8(2)(b) of Regulation (EU) 2020/852, was calculated by dividing the numerator by the denominator. The OpEx denominator includes non-capitalized direct costs related to research and development, building renovation measures, short-term leases, maintenance and repairs, as well as other direct costs related to the day-to-day maintenance of property, plant and equipment by the company or a third-party subcontractor to ensure the continued efficient operation of these assets. Leasing costs for non-financial companies that apply national GAAP and do not capitalize right-of-use assets are also included in the OpEx.

In this case, the OpEx indicator calculation covers:

- Direct non-capitalized costs associated with research and development
- Short-term leases
- Maintenance and repair costs

However, other expenses related to the day-to-day maintenance of property, plant and equipment, such as cleaning services or repairs to computer systems, have not been included in the numerator calculation, in compliance with Article 8 of the regulations and the accounting methodology adopted by Grifols to present these expenses. Furthermore, as a precautionary measure, those situations in which an expense account was not sufficiently detailed to be able to determine whether it was a maintenance expense directly linked to any of the taxonomic activities analyzed, or other types of maintenance such as those mentioned above, have not been considered as eligible.

Accordingly, the denominator of the indicator includes the total expenditure of these three Grifols items, while the numerator is composed of the same items, but only for the activities that have been recognized as eligible in accordance with the established criteria.

Results

The following tables set out the data corresponding to turnover, CapEx and OpEx for Grifols' economic activities that comply with the European Taxonomy.

Grifols Results

Turnover

Financial year 2023	Year 2023			Substantial Contribution Criteria						DNSH criteria ("Does Not Significantly Harm")										
	Economic Activities (1)	Code (2)	Turnover (3)	Proportion of Turnover 2023 (4)	Climate Change Mitigation (5)	Climate Change Adaptation (6)	Water (7)	Pollution (8)	Circular Economy (9)	Biodiversity (10)	Climate Change Mitigation (11)	Climate Change Adaptation (12)	Water (13)	Pollution (14)	Circular Economy (15)	Biodiversity (16)	Minimum Safeguards (17)	Proportion of Taxonomy-aligned (A.1) or -eligible (A.2) turnover, 2023 (18)	Category enabling activity (19)	Category transitional activity (20)
Text		EUR	%	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S/N	S/N	S/N	S/N	S/N	S/N	S/N	%	F	T
A. TAXONOMY-ELIGIBLE ACTIVITIES																				
A.1. Environmentally sustainable activities (Taxonomy-aligned)																				
Turnover of environmentally sustainable activities (Taxonomy-aligned) (A.1)		0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0%		
Of which Enabling		0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0%	F	
Of which Transitional		0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0%		T
A.2 Taxonomy-Eligible but not environmentally sustainable activities (not Taxonomy-aligned activities)																				
1.2 Manufacture of medicinal products	PPC 1,2	5,096,622,614.77	83.14%	N/EL	N/EL	N/EL	EL	N/EL	N/EL									*2		
Turnover of Taxonomy-eligible but not environmentally sustainable activities (not Taxonomy-aligned activities) (A.2)		5,096,622,614.77	83.14%	0%	0%	0%	83.14%	0%	0%									0%		
"A. Turnover of Taxonomy eligible activities (A.1+A.2)"		5,096,622,614.77	83.14%	0%	0%	0%	83.14%	0%	0%									0%		
B. TAXONOMY-NON-ELIGIBLE ACTIVITIES																				
Turnover of Taxonomy-non-eligible activities		1,033,676,332.41	16.86%																	
TOTAL		6,130,298,947.18	100%																	

*1 All activities added in 2023 were not checked for taxonomy conformity

*2 Economic activity is to be reported for the first time for FY 2023 or did not exist in the previous year, so no previous year's figures are reported here.

*3 Not applicable, as alignment is to be reviewed for the first time for the 2024 financial year for the other 4 environmental targets.

	Proportion of turnover/Total turnover	
	Taxonomy-aligned per objective	Taxonomy-eligible per objective
CCM	0%	0%
CCA	0%	0%
WTR	*3	0%
CE	*3	0%
PPC	*3	83.14%
BIO	*3	0%

CapEx

Financial year 2023	Year 2023			Substantial Contribution Criteria						DNSH criteria ('Does Not Significantly Harm')									
	Code (2)	CapEx (3)	Proportion o CapEx (4) ¹	Climate Change Mitigation (5)	Climate Change Adaption (6)	Water (7)	Pollution (8)	Circular Economy (9)	Biodiversity (10)	Climate Change Mitigation (11)	Climate Change Adaption (12)	Water (13)	Pollution (14)	Circular Economy (15)	Biodiversity (16)	Minimum Safeguards (17)	Taxonomy-aligned proportion of CapEx, 2022 (18)	Category enabling activity (19)	Category transitional activity (20)
Text		EUR	%	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S/N	S/N	S/N	S/N	S/N	S/N	S/N	%	F	T
A. TAXONOMY-ELIGIBLE ACTIVITIES																			
A.1. Environmentally sustainable activities (Taxonomy-aligned)																			
7.4 Installation, maintenance and repair of charging stations for electric vehicles in buildings (and parking spaces attached to buildings)	CCM 7,4	12,760.39	0.008%	S	N/EL	N/EL	N/EL	N/EL	N/EL	S	S	S	S	S	S	S	0%		
CapEx of environmentally sustainable activities (Taxonomy-aligned) (A.1)		12,760.39	0.008%	0.008%	0%	0%	0%	0%	0%	S	S	S	S	S	S	S	0%		
Of which Enabling		0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	0%	F	
Of which Transitional		0	0	-						-	-	-	-	-	-	-	0%		T
A.2 Taxonomy-Eligible but not environmentally sustainable activities (not Taxonomy-aligned activities)																			
7.3, Instalación, mantenimiento y reparación de equipos de eficiencia energética	CCM 7,3	70,435.54	0.044%	EL	N/EL	N/EL	N/EL	N/EL	N/EL								*2		
1.2 Manufacture of medicinal products	PPC 1,2	131,999,777.39	82.37%	N/EL	N/EL	N/EL	EL	N/EL	N/EL								*2		
CapEx of Taxonomy-eligible but not environmentally sustainable activities (not Taxonomy-aligned activities) (A.2)		132,070,212.93	82.417%	0.044%	0%	0%	82.37%	0%	0%								0%		
A. CapEx of Taxonomy eligible activities (A.1+A.2)		132,082,973.32	82.42%	0.052%	0%	0%	82.37%	0%	0%										
B. TAXONOMY-NON-ELIGIBLE ACTIVITIES																			
CapEx of Taxonomy non-eligible activities		28,164,150.29	17.58%																
TOTAL		160,247,123.61	100%																

*1 All activities added in 2023 were not checked for taxonomy conformity

*2 Economic activity is to be reported for the first time for FY 2023 or did not exist in the previous year, so no previous year's figures are reported here.

*3 Not applicable, as alignment is to be reviewed for the first time for the 2024 financial year for the other 4 environmental targets.

	Proportion of CapEx/Total CapEx	
	Taxonomy-aligned per objective	Taxonomy-eligible per objective
CCM	0.008%	0.052%
CCA	0%	0%
WTR	*3	0%
CE	*3	0%
PPC	*3	82.37%
BIO	*3	0%

OpEx

Financial year 2023	Year 2023			Substantial Contribution Criteria						DNSH criteria ('Does Not Significantly Harm')										
	Economic Activities (1)	Code (2)	OpEx (3)	Proportion of OpEx 2023 (4)	Climate Change Mitigation (5)	Climate Change Adaptation (6)	Water (7)	Pollution (8)	Circular Economy (9)	Biodiversity (10)	Climate Change Mitigation (11)	Climate Change Adaptation (12)	Water (13)	Pollution (14)	Circular Economy (15)	Biodiversity (16)	Minimum Safeguards (17)	Proportion of Taxonomy-aligned (A.1) or -eligible (A.2), OpEx, 2022 (18)	Category enabling activity (19)	Category transitional activity (20)
Text		EUR	%	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S/N	S/N	S/N	S/N	S/N	S/N	S/N	%	F	T
A. TAXONOMY-ELIGIBLE ACTIVITIES																				
A.1. Environmentally sustainable activities (Taxonomy-aligned)																				
OpEx of environmentally sustainable activities (Taxonomy-aligned) (A.1)		0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0%		
Of which Enabling		0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0%	F	
Of which Transitional		0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0%		T
A.2 Taxonomy-Eligible but not environmentally sustainable activities (not Taxonomy-aligned activities)																				
1.1 Conservation, including restoration, of habitats, ecosystems and species		BIO 1,1	123,985.32	0.07%	N/EL	N/EL	N/EL	N/EL	N/EL	EL								*2		
1.2 Manufacture of medicinal products		PPC 1,2	45,176,289.89	24.76%	N/EL	N/EL	N/EL	EL	N/EL	N/EL								*2		
OpEx of Taxonomy-eligible but not environmentally sustainable activities (not Taxonomy-aligned activities) (A.2)		45,300,275.21	24.83%	0%	0%	0%	24.76%	0%	0.07%									0%		
A. OpEx of Taxonomy eligible activities (A.1+A.2)*1		45,300,275.21	24.83%	0%	0%	0%	24.76%	0%	0.07%											
B. TAXONOMY-NON-ELIGIBLE ACTIVITIES																				
OpEx of Taxonomy-non-eligible activities		137,135,261.76	75.17%																	
TOTAL		182,435,536.97	100%																	

*1 All activities added in 2023 were not checked for taxonomy conformity

*2 Economic activity is to be reported for the first time for FY 2023 or did not exist in the previous year, so no previous year's figures are reported here.

*3 Not applicable, as alignment is to be reviewed for the first time for the 2024 financial year for the other 4 environmental targets.

	Proportion of OpEx/Total OpEx	
	Taxonomy-aligned per objective	Taxonomy-eligible per objective
CCM	0%	0%
CCA	0%	0%
WTR	*3	0%
CE	*3	0%
PPC	*3	24.76%
BIO	*3	0.07%

Scope of the European Taxonomy Analysis

In line with the rest of the Annual Integrated and Sustainability Report, the data tables for Grifols Consolidated and the Biotest Group is presented separately to facilitate data comparison. The taxonomy study for Grifols Consolidated is presented in the previous sections. The eligibility and alignment analysis is published by Biotest Group annually along with management approaches and main application policies at www.biotest.com. The main results are presented in section "Biotest Results" in this Appendix.

Biotest results

Turnover

Financial year 2023	Year 2023			Substantial Contribution Criteria						DNSH criteria ('Does Not Significantly Harm')									
Economic Activities (1)	Code (2)	Volumen de negocios (3)	Proportion of Turnover, year 2023 (4)	Climate Change Mitigation (5)	Climate Change Adaptation (6)	water (7)	Pollution (8)	Circular Economy (9)	Biodiversity (10)	Climate Change Mitigation (11)	Climate Change Adaptation (12)	Water (13)	Pollution (14)	Circular Economy (15)	Biodiversity (16)	Minimum Safeguards (17)	Proportion of Taxonomy aligned (A.1.) or eligible (A.2.) Turnover, year 2022 (18)	Category enabling activity (19)	Category transitional activity (20)
Text	EUR		%	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S/N	S/N	S/N	S/N	S/N	S/N	S/N	%	F	T
A. TAXONOMY-ELIGIBLE ACTIVITIES																			
A.1. Environmentally sustainable activities (Taxonomy-aligned)																			
Turnover of environmentally sustainable activities (Taxonomy-aligned) (A.1)		0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	0		
Of which Enabling		0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	0	F	
Of which Transitional		0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	0		T
A.2 Taxonomy-Eligible but not environmentally sustainable activities (not Taxonomy-aligned activities)																			
1.2 Manufacture of medicinal products	PPC 1,2	487,986,519.87	71.28	N/EL	N/EL	N/EL	EL	N/EL	N/EL								-		
Turnover of Taxonomy-eligible but not environmentally sustainable activities (not Taxonomy-aligned activities) (A.2)		487,986,519.87	71.28	0%	0%	0%	71.28%	0%	0%								0%		
"A. Turnover of Taxonomy eligible activities (A.1+A.2)		487,986,519.87	71.28	0%	0%	0%	71.28%	0%	0%								0%		
B. TAXONOMY-NON-ELIGIBLE ACTIVITIES																			
Turnover of Taxonomy non-eligible activities		196,612,445.82	28.72																
TOTAL		684,598,965.69	100%																

*1 All activities added in 2023 were not checked for taxonomy conformity

*2 Economic activity is to be reported for the first time for FY 2023 or did not exist in the previous year, so no previous year's figures are reported here.

*3 Not applicable, as alignment is to be reviewed for the first time for the 2024 financial year for the other 4 environmental targets.

	Proportion of turnover/Total turnover	
	Taxonomy-aligned per objective	Taxonomy-eligible per objective
CCM	0%	0%
CCA	0%	0%
WTR	*3	0%
CE	*3	0%
PPC	*3	71,28%
BIO	*3	0%

CapEx

Financial year 2023	Year 2023			Substantial Contribution Criteria						DNSH criteria ('Does Not Significantly Harm')									
Economic Activities (1)	Code (2)	CapEx (3)	Proporcion del CapEx año 2023 (4)	Climate Change Mitigation (5)	Climate Change Adaption (6)	water (7)	Pollution (8)	Circular Economy (9)	Biodiversity (10)	Climate Change Mitigation (11)	Climate Change Adaption (12)	Water (13)	Pollution (14)	Circular Economy (15)	Biodiversity (16)	Minimum Safeguards (17)	Proportion of Taxonomy aligned (A.1.) or eligible (A.2.) CapEx, year 2022 (18)	Category enabling activity (19)	Category transitional activity (20)
Text		EUR	%	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S/N	S/N	S/N	S/N	S/N	S/N	S/N	%	F	T
A. TAXONOMY-ELIGIBLE ACTIVITIES																			
A.1. Environmentally sustainable activities (Taxonomy-aligned)																			
CapEx of environmentally sustainable activities (Taxonomy-aligned) (A.1)		0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	0		
Of wich Enabling		0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	0	F	
Of wich Transitional		0	0	-						-	-	-	-	-	-	-	0		T
A.2 Taxonomy-Eligible but not environmentally sustainable activities (not Taxonomy-aligned activities) (g)																			
1.2 Manufacture of medicinal products	PPC 1,2	41,522,832.53	59.81	N/EL	N/EL	N/EL	EL	N/EL	N/EL								-*2		
3.2 Renovation of existing buildings	CE 3,2 CCM 7,2 CCA 7,2	570,854.85	0.82	N/EL	N/EL	N/EL	N/EL	EL	N/EL								-*2		
4.1 Electricity generation using solar photovoltaic technology	CCM 4,1 CCA 4,1	939,000.00	1.35	EL	N/EL	N/EL	N/EL	N/EL	N/EL								0.47		
4.25 Production of heat/cool using waste heat	CCM 4,25 CCA 4,25	369,174.23	0.53	EL	N/EL	N/EL	N/EL	N/EL	N/EL								-*2		
5.4 Reneal of waste water collection and treatment	CCM 5,4 CCA 5,4	189,380.48	0.27	EL	N/EL	N/EL	N/EL	N/EL	N/EL								-*2		
6.5 Transport of motorbikes, passenger cars and light commercial vehicles	CCM 6,5 CCA 6,5	491,574.41	0.71	EL	N/EL	N/EL	N/EL	N/EL	N/EL								1.26%		
7.4 Installation, maintenance and repair of charging stations for electric vehicles in buildings (and parking spaces attached to buildings)	CCM 7,4 CCA 7,4	17,458.00	0.03	EL	N/EL	N/EL	N/EL	N/EL	N/EL								0.26%		
7.5 Installation, maintenance and repair of instruments and devices for measuring, regulation and controlling energy performance of buildings	CCM 7,5 CCA 7,5	91,962.00	0.13	EL	N/EL	N/EL	N/EL	N/EL	N/EL								0.24%		
8.1 Data processing, hosting and related activities	CCM 8,1 CCA 8,1	260,570.00	0.38	EL	N/EL	N/EL	N/EL	N/EL	N/EL								0.03%		
CapEx of Taxonomy eligible but not environmentally sustainable activities (not Taxonomy-aligned activities) (A.2)		44,452,806.50	64.03	3.40%	0%	0%	59.81%	0.82%	0%								2.35%		
A. CapEx of Taxonomy eligible activities (A.1+A.2)		44,452,806.50	64.03	3.40%	0%	0%	59.81%	0.82%	0%								2.35%		
B. TAXONOMY-NON-ELIGIBLE ACTIVITIES																			
Taxonomy-noneligible activitie		24,975,199.89	35.97																
TOTAL		69,428,006.39	100%																

	Proportion of CapEx/Total CapEx	
	Taxonomy-aligned per objective	Taxonomy-eligible per objective
CCM	0%	4,22%
CCA	0%	4,22%
WTR	*3	0%
CE	*3	0,82%
PPC	*3	76,02%
BIO	*3	0%

*1 All activities added in 2023 were not checked for taxonomy conformity

*2 Economic activity is to be reported for the first time for FY 2023 or did not exist in the previous year, so no previous year's figures are reported here.

*3 Not applicable, as alignment is to be reviewed for the first time for the 2024 financial year for the other 4 environmental targets.

OpEx

Financial year 2023	Year 2023			Substantial Contribution Criteria						DNSH criteria ('Does Not Significantly Harm')									
Economic Activities (1)	Code (2)	OpEx (3)	Proportión del OpEx año 2023 (4)	Climate Change Mitigation (5)	Climate Change Adaption (6)	water (7)	Pollution (8)	Circular Economy (9)	Biodiversity (10)	Climate Change Mitigation (11)	Climate Change Adaption (12)	Water (13)	Pollution (14)	Circular Economy (15)	Biodiversity (16)	Minimum Safeguards (17)	Proportion of Taxonomy aligned (A.1.) or eligible (A.2.) OpEx, year 2022 (18)	Category enabling activity (19)	Category transitional activity (20)
Text		EUR	%	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S, N, N/EL (b) (c)	S/N	S/N	S/N	S/N	S/N	S/N	S/N	%	F	T
A. TAXONOMY-ELIGIBLE ACTIVITIES																			
A.1. Environmentally sustainable activities (Taxonomy-aligned)																			
OpEx of environmentally sustainable activities (Taxonomy-aligned) (A.1)		0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	0		
Of wich Enabling		0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	0	F	
Of wich Transitional		0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	0		T
A.2 Taxonomy-Eligible but not environmentally sustainable activities (not Taxonomy-aligned activities) (g)																			
1.2 Manufacture of medicinal products	PPC 1,2	79,821,353.90	89.22	N/EL	N/EL	N/EL	EL	N/EL	N/EL								-*2		
2.4 Remediation of contaminated sites	PPC 2,4	35,206.69	0.04	N/EL	N/EL	N/EL	EL	N/EL	N/EL								-*2		
4.9 Transmission and distribution of electricity	CCM 4,9 CCA 4,9	115,610.00	0.13	EL	N/EL	N/EL	N/EL	N/EL	N/EL								0.23%		
4.11 Storage of thermal energy	CCM 4,11 CCA 4,11	30,580.00	0.03	EL	N/EL	N/EL	N/EL	N/EL	N/EL								0.12%		
4.30 High-efficiency co-generation of heat/cool and power from fossil gaseous fuels	CCM 4,30 CCA 4,30	169,943.00	0.19	EL	N/EL	N/EL	N/EL	N/EL	N/EL								0.16%		
5.3 Construction, extension and operation of waste water collection and treatment	CCM 5,3 CCA 5,3	100,446.00	0.11	EL	N/EL	N/EL	N/EL	N/EL	N/EL								0.24%		
5.4 Renewal of waste water collection and treatment	CCM 5,4 CCA 5,4	74,085.70	0.08	EL	N/EL	N/EL	N/EL	N/EL	N/EL								0.41%		
6.5 Transport by motorbikes, passenger cars and light commercial vehicles	CCM 6,5 CCA 6,5	265,677.93	0.30	EL	N/EL	N/EL	N/EL	N/EL	N/EL								0.33%		
6.6 Freight transport services by road	CCM 6,6 CCA 6,6	91,879.72	0.10	EL	N/EL	N/EL	N/EL	N/EL	N/EL								0.04%		
7.3 Installation, maintenance and repair of energy efficiency equipment	CCM 7,3	2,523,226.00	2.82	EL	N/EL	N/EL	N/EL	N/EL	N/EL								0.03		
7.5 Installation, maintenance and repair of instruments and devices for measuring, regulation and controlling energy performance of buildings	CCM 7,5	255,525.00	0.29	EL	N/EL	N/EL	N/EL	N/EL	N/EL								0.39%		
8.1 Data processing, hosting and related activities	CCM 8,1 CCA 8,1	471,612.27	0.53	EL	N/EL	N/EL	N/EL	N/EL	N/EL								0.01%		
OpEx of Taxonomy eligible but not environmentally sustainable activities (not Taxonomy-aligned activities) (A.2)*1		83,955,146	93.84	4.58%	0%	0%	0.00%	89.26%	0%								4.65%		
A. OpEx of Taxonomy eligible activities (A.1+A.2)		83,955,146	93.84	4.58%	0%	0%	0.00%	89.26%	0%								4.65%		
B. TAXONOMY-NON-ELIGIBLE ACTIVITIES																			
Taxonomy-noneligible activitie		5,508,294	6.16																
TOTAL		89,463,439.86	100%																

*1 All activities added in 2023 were not checked for taxonomy conformity

*2 Economic activity is to be reported for the first time for FY 2023 or did not exist in the previous year, so no previous year's figures are reported here.

*3 Not applicable, as alignment is to be reviewed for the first time for the 2024 financial year for the other 4 environmental targets.

	Proportion of turnover/Total turnover	
	Taxonomy-aligned per objective	Taxonomy-eligible per objective
CCM	0%	4,58%
CCA	0%	1,44%
WTR	*3	0%
CE	*3	0%
PPC	*3	89,26%
BIO	*3	0%

Annex VI.

Law 11/2018 content index. Information requested by the Law 11/2018

The selected GRI Disclosures below refer to those published in 2016, except those that have undergone and in which case the year of publication is indicated

LAW 11/2018 CONTENT INDEX			
Information requested by the Law 11/2018	Materiality	Page number(s)	Reporting criteria: GRI (last version except indicated)
General information			
A brief description of the business model that includes its business environment, its organization and structure	Material	11, 16-17	GRI 2-6 (2021)
Markets in which it operates	Material	14-15	GRI 2-1 (2021) GRI 2-6 (2021)
Objectives and strategies of the organization	Material	19, 28-29, 92, 134, 212, 218	GRI 2-1 (2021) GRI 2-22 (2021)
Main factors and trends that can affect its future evolution	Material	233-239	GRI 3-3 (2021) GRI 2-22 (2021)
Reporting framework used	Material	269-270	GRI 1 (2021)
Principle of materiality	Material	20-27	GRI 3-1 (2021) GRI 3-2 (2021)
Environmental Issues			
Management approach: description and results of the policies related to these issues, as well as the main risks related to those issues related to the group's activities.	Material	93-94, 96, 99-100, 221	GRI 3-3 (2021)
Detailed general information			
Detailed information on the actual and predictable effects of the company's activities on the environment and, when applicable, health and safety.	Material	101-102	GRI 3-3 (2021)
Environmental assessment or certification procedures	Material	95	GRI 3-3 (2021)
Resources dedicated to the prevention of environmental risks	Material	97	GRI 3-3 (2021)
Application of the precautionary principle	Material	93-94, 97	GRI 2-23 (2021)
Amount of provisions and guarantees for environmental risks	Material	97-98, 119	GRI 3-3 (2021)
Contamination			
Measures to prevent, reduce or repair emissions that seriously affect the environment; considering any form of activity-specific air pollution, including noise and light pollution	Material	104, 120-121	GRI 3-3 (2021) GRI 305-7
Circular Economy and Waste Prevention and Management			
Prevention, recycling, reutilization and other recovery and waste disposal measures.	Material	110, 114-115, 130-132	GRI 306-1 GRI 306-2 GRI 306-4 GRI 306-5
Actions to fight food waste	Not Material	-	-
Sustainable Use of Resources			
Water consumption and supply in accordance with the local limitations	Material	112-113, 124-128	GRI 303-1 a 303-5
Consumption of raw materials and measures taken to improve the efficiency of their use	Material	110-111, 133	GRI 301-1
Direct and indirect energy consumption	Material	105-109, 121-124, 129	GRI 302-1 GRI 302-3
Measures taken to improve energy efficiency	Material	99, 105, 108	GRI 3-3 (2021) GRI 201-2
Use of renewable energy	Material	108, 124	GRI 302-1
Climate Change			
Greenhouse gas emissions generated as a result of the company's activities, including the use of the goods and services it produces	Material	103-104, 119-121	GRI 305-1 GRI 305-2 GRI 305-3 GRI 305-4
Measures taken to adapt to the consequences of climate change	Material	102, 104	GRI 3-3 (2021) GRI 201-2
Voluntary measures for medium and long-term reduction goals to reduce greenhouse gas emissions and the means implemented for this purpose	Material	102-104	GRI 3-3 (2021)

LAW 11/2018 CONTENT INDEX			
Information requested by the Law 11/2018	Materiality	Page number(s)	Reporting criteria: GRI (last version except indicated)
Biodiversity Protection			
Measures taken to preserve or restore biodiversity	Material	116-118	GRI 3-3 (2021)
Impacts caused by activities or operations in protected areas	Material	116-118	GRI 3-3 (2021)
Social and Personnel matters			
Management approach: description and results of the policies related to these matters as well as the main risks related to those issues linked to the group's activities.	Material	134-137, 221	GRI 3-3 (2021)
Employment			
Total number and distribution of employees by country, gender, age and professional category	Material	138-139, 167 - 177	GRI 405-1
Total number and distribution of employment contract modalities and annual average of indefinite contracts, temporary contracts and part-time contracts by gender, age and professional category	Material	167-177	GRI 2-7 (2021)
Number of dismissals by gender, age and professional classification	Material	178-179	GRI 3-3 (2021) GRI 401-1
Average remuneration and its evolution disaggregated by sex, age and professional classification or equal value	Material	155, 186-188	GRI 3-3 (2021)
Gender gap, the remuneration of equal or average company jobs	Material	156-159, 189-190	GRI 3-3 (2021) GRI 405-2
Average remuneration of directors and executives, including variable remuneration, allowances, allowances, payment to long-term savings forecasting systems and any other perception disaggregated by sex	Material	31, 188, 219	GRI 3-3 (2021)
Implementation of policies work disconnection	Material	137, 166	GRI 3-3 (2021)
Number of employees with disabilities	Material	143	GRI 3-3 (2021) GRI 405-1
Organization of Work			
Organization of working time	Material	166	GRI 3-3 (2021)
Number of hours of absenteeism	Material	180-181	GRI 3-3 (2021) GRI 403-9
Measures aimed at facilitating the enjoyment of conciliation and promoting the co-responsible exercise of these by both parents	Material	166	GRI 3-3 (2021) GRI 403-3
Health and Safety			
Health and safety conditions at work	Material	162-165	GRI 3-3 (2021) GRI 403-1 GRI 403.3 GRI 403-4 GRI 403-5 GRI 403-6 GRI 403-7
Occupational accidents, their frequency and severity, as well as occupational diseases; disaggregated by gender	Material	165, 185	GRI 403-9 GRI 403-10
Social Relationships			
Organization of social dialogue including procedures for informing and consulting staff and negotiating with them	Material	160	GRI 3-3 (2021)
Mechanisms and procedures that the company has to promote the involvement of workers in the management of the company, in terms of information, consultation and participation	Material	160	GRI 3-3 (2021)
Percentage of employees covered by collective agreement by country	Material	160	GRI 2-30 (2021)
Balance of collective agreements, particularly in the field of health and safety at work	Material	160	GRI 3-3 (2021) GRI 403-4
Training			
Policies implemented in the field of training	Material	136, 150-151	GRI 404-2
Total number of training hours by professional category	Material	152, 181-183	GRI 3-3 (2021) GRI 404-1
Universal accessibility			
Integration and universal accessibility of people with disabilities	Material	143	GRI 3-3 (2021)
Equality			
Measures taken to promote equal treatment and opportunities for women and men	Material	136, 140	GRI 3-3 (2021)
Equality plans, measures taken to promote employment, protocols against sexual and gender harassment	Material	142, 144 - 145	GRI 3-3 (2021)
Policy against all types of discrimination and, when applicable, diversity management	Material	136, 140-142	GRI 3-3 (2021)

LAW 11/2018 CONTENT INDEX			
Information requested by the Law 11/2018	Materiality	Page number(s)	Reporting criteria: GRI (last version except indicated)
Respect for human rights			
Management approach: description and results of the policies related to these matters as well as the main risks related to those issues linked to the group's activities.	Material	32-35, 38, 41, 221	GRI 3-3 (2021)
Application of due diligence procedures			
Application of due diligence procedures in the field of human rights and prevention of risks of violation of human rights and, where appropriate, measures to mitigate, manage and repair possible abuses committed	Material	32-35	GRI 2-23 (2021)
Complaints for cases of human rights violation	Material	232	GRI 3-3 (2021) GRI 406-1 (2016)
Measures implemented to promote and comply with the provisions of the ILO fundamental conventions related to respect for freedom of association and the right to collective bargaining; the elimination of discrimination in employment and occupation; the elimination of forced or compulsory labor; the effective abolition of child labor	Material	32-33, 142	GRI 3-3 (2021)
Fight against corruption and bribery			
Management approach: description and results of the policies related to these matters as well as the main risks related to those issues linked to the group's activities.	Material	221, 225-227	GRI 3-3 (2021)
Measures taken to prevent corruption and bribery	Material	221, 225-231	GRI 3-3 (2021) GRI 2-23 (2021) GRI 205-1 a 205-3
Measures to fight money laundering	Material	227	GRI 3-3 (2021) GRI 2-23 (2021) GRI 205-1 a 205-3
Contributions to foundations and NGOs	Material	228-229, 278-279	GRI 2-28 (2021) GRI 201-1 GRI 415-1
Information about society			
Management approach: description and results of the policies related to these matters as well as the main risks related to those issues linked to the group's activities.	Material	194-197, 221	GRI 3-3 (2021)
Commitment of the company to sustainable development			
The impact of the company's activity on employment and local development	Material	197-201	GRI 3-3 (2021) GRI 203-2
The impact of society's activity on local populations and in the territory	Material	194, 196-197, 199	GRI 3-3 (2021)
The relations maintained with the actors of the local communities and the modalities of the dialogue with these	Material	26-27, 195-201	GRI 2-29 (2021)
Partnership or sponsorship actions	Material	195-201, 208-211, 279	GRI 3-3 (2021) GRI 201-1
Subcontracting and suppliers			
Inclusion in the purchasing policy of social, gender equality and environmental issues	Material	37-38, 41	GRI 3-3 (2021)
Consideration in the relations with suppliers and subcontractors of their social and environmental responsibility	Material	37-39, 41	GRI 2-6 (2021)
Supervision and audit systems and their results	Material	39, 51	GRI 2-6 (2021)
Consumers			
Measures for the health and safety of consumers	Material	44, 46-50, 222-224	GRI 3-3 (2021) GRI 416-1
Complaint systems, complaints received and resolution thereof	Material	48	GRI 3-3 (2021) GRI 418-1
Tax information			
Profit obtained country by country	Material	267	GRI 3-3 (2021) GRI 207-4
Taxes earned on benefits paid (per country)	Material	216, 267	GRI 3-3 (2021) GRI 201-1 GRI 207-4
Public grants received (per country)	Material	251	GRI 3-3 (2021)
EU Taxonomy	Material	280-289	KPIs developed according to the methodology described in this report

Annex VII.

GRI Content Index

GRI Standards	GRI Disclosure	Page number, URL and/or direct response	Omission
Statement of use	Grifols S.A. has reported in accordance with the GRI Standards for the period January 1st to December 31st of 2023.		
GRI 1: Foundation 2021			
General Disclosures			
	The organization and its reporting practices		
	2 - 1	Organizational details 14-15,266-267	
	2 - 2	Entities included in the organization's sustainability reporting 271-272	
	2 - 3	Reporting period, frequency and contact point 271 Contact: investors@grifols.com / sustainability@grifols.com	
	2 - 4	Restatements of information All information with a temporal or organizational scope other than 2022 or 2021 is properly indicated and accompanied by a clarification.	
	2 - 5	External assurance 301-302	
	Activities and workers		
	2 - 6	Activities, value chain, and other business relationships 11-17, 37-39	No information available related to the requirement b-iii
	2 - 7	Employees 167-177 Grifols does not hire employees without assigned hours	
	2 - 8	Workers who are not employees -	Not applicable
	Governance		
	2 - 9	Governance structure and composition 213-218 IAGC (section C) https://www.grifols.com/en/annual-corporate-governance-report	
GRI 2: General Disclosures 2021	2 - 10	Nomination and selection of the highest governance body IAGC (section C) https://www.grifols.com/en/annual-corporate-governance-report Policy on Director Diversity in the composition of the Board of Directors Grifols S.A. https://www.grifols.com/documents/3625622/3684243/Grifols+-+Politica+de+diversidad+-+Dic.+2020+-+ES.PDF/e054c860-a308-46eb-af53-5ca7b187e0dd?t=1608130227711	
	2 - 11	Chair of the highest governance body 214-217	
	2 - 12	Role of the highest governance body in overseeing the management of impacts 30	
	2 - 13	Delegation of responsibility for managing impacts 30	
	2 - 14	Role of the highest governance body in sustainability reporting 30	
	2 - 15	Conflicts of interest IAGC (section C) https://www.grifols.com/en/annual-corporate-governance-report	
	2 - 16	Communication of critical concerns 214	
	2 - 17	Collective knowledge of the highest governance body 153	
	2 - 18	Evaluation of the performance of the highest governance body IAGC (section C) https://www.grifols.com/en/annual-corporate-governance-report	
	2 - 19	Remuneration policies 31, 219-220 Remuneration Policy for Directors of Grifols, S.A. https://www.grifols.com/documents/3625622/5421064/Directors-Remuneration-Policy-proposal-ES.pdf/6c8473e3-947d-0d5f-1d6b-e3bb992fa8ff?t=1686904260735	

GRI Standards	GRI Disclosure	Page number, URL and/or direct response	Omission	
GRI 2: General Disclosures 2021	2 - 20	Process to determine remuneration 20 Remuneration Policy for Directors of Grifols, S.A. https://www.grifols.com/documents/3625622/4076106/20220610-Directors-Remuneration-Policy-proposal-EN.pdf/6d5fdb79-3f9d-d73a-39f9-753c1a4981e3?t=1654852418449		
	2 - 21	Annual total compensation ratio	- Not reported due to confidentiality constraints	
	Strategy, policies and practices			
	2 - 22	Statement on sustainable development strategy	6, 19	
	2 - 23	Policy commitments	19, 28-29, 38, 92-94, 134, 136, 212, 218, 221	
	2 - 24	Embedding policy commitments	19, 28-29, 38, 92-94, 134, 136, 212, 218, 221	
	2 - 25	Processes to remediate negative impacts	46, 226-227, 232	
	2 - 26	Mechanisms for seeking advice and raising concerns	27, 232 "During the course 2023, Biotest has not received any formal complaints through its designated channel. However, the company have received receive 9 communications through internal reports to higher positions or the Human Resources team. Among these communications, 2 correspond to matters concerning compliance with standards, norms, processes, or laws, as well as inappropriate behavior. No formal reports or complaints have been made regarding sexual harassment, discrimination, conflict of interest, health and safety or corruption"	
	2 - 27	Compliance with laws and regulations	49-50, 97, 222, 225-226, 232	
	2 - 28	Membership associations	228-229, 278-279	
	Stakeholder engagement			
2 - 29	Approach to stakeholder engagement	26-27		
2 - 30	Collective bargaining agreements	160		
Material Topics				
GRI 3: Material Topics 2021	3 - 1	Process to determine material topics	20-25	
	3 - 2	List of material topics	21, 24-25	
Circular economy and resource management				
GRI 3: Material Topics 2021	3 - 3	Management of material topics	93-94, 99-100, 221 No information available related to the requirements a, b, d, e, f	
GRI 301: Materials 2016	301-1	Materials used by weight or volume	133 Given the nature of the materials used by Grifols, the breakdown by renewable and non-renewable is not applicable.	
GRI 303: Water and Effluents 2018	303-1	Interactions with water as a shared resource	93, 100, 112-113 No information available related to the requirement c.	
	303-2	Management of water discharge-related impacts	113	
	303-3	Water withdrawal	112-113, 124-128 No information available related to the requirement c.	
	303-4	Water discharge	112-113, 124-128 No information available related to the requirements b, c.	
	303-5	Water consumption	112-113, 124-128	
GRI 306: Waste 2020	306-1	Waste generation and significant waste-related impacts	110, 114-115	
	306-2	Management of significant waste-related impacts	110, 114-115 Management platforms, tracking sheets, internal spreadsheets and reports from waste managers are used to collect and track data associated with waste quantities. This data is fed into the SAP Sustainability Performance Management platform. Information regarding significant waste-related impacts is not available for publication in this report. Specific measures are being taken in the collection of information and the data processing process to be able to provide this detail in the next five years.	
	306-4	Waste diverted from disposal	114, 130-131 No information available related to the requirement d.	
	306-5	Waste directed to disposal	114, 130-131 No information available related to the requirement d.	

GRI Standards	GRI Disclosure	Page number, URL and/or direct response	Omission	
Climate change				
GRI 3: Material Topics 2021	3 - 3	Management of material topics	93-94, 99, 101-104, 221	No information available related to the requirements a, b, d, e, f
GRI 201: Economic Performance 2016	201-2	Financial implications and other risks and opportunities due to climate change	101-102, 119	
GRI 305: Emissions 2016	305-1	Direct (Scope 1) GHG emissions	103-104, 119-121	
	305-2	Energy indirect (Scope 2) GHG emissions	103-104, 119-121	
	305-3	Other indirect (Scope 3) GHG emissions	103-104, 119-121	
	305-4	GHG emissions intensity	121	
	305-6	Emissions of ozone-depleting substances (ODS)	104	No information available related to the requirements a, c
	305-7	Nitrogen oxides (NOX), sulfur oxides (SOX), and other significant air emissions	103-104,120-121	No information available related to the requirements a-iii, iv, v, vi
Energy Efficiency				
GRI 3: Material Topics 2021	3 - 3	Management of material topics	93-94, 99, 105-109, 221	No information available related to the requirements a, b, d, e, f
GRI 302: Energy 2016	302-1	Energy consumption within the organization	105-109, 121-124	
	302-3	Energy intensity	122-124 All ratios are reported using energy consumption within the organization	
	302-4	Reduction of energy consumption	105-109	
Human rights				
GRI 3: Material Topics 2021	3 - 3	Management of material topics	32-35, 38, 41, 221	No information available related to the requirements a, b, d, e, f
Ethical code and good business practices				
GRI 3: Material Topics 2021	3 - 3	Management of material topics	221	No information available related to the requirements a, b, d, e, f
GRI 205: Anti-corruption 2016	205-1	Operations assessed for risks related to corruption	225, 227, 235-236	No information available related to the requirement a, regarding to the percentage of operations assessed for risks related to corruption.
	205-2	Communication and training about anti-corruption policies and procedures	<p>“Total number of governance body members that the organization’s anti-corruption policies and procedures have been communicated to: 3 (USA) and 26 (Europe) for Grifols and 6 (Europe) for Biotest. Total: 35. Total number of governance body members that have received training on anti-corruption: Grifols: 3 (USA) and 26 (Europe) and Biotest: 6 (Europe). Total: 35.</p> <p>Grifols’ employees most likely to witness cases of corruption have been informed of anti-corruption policies and procedures in 2023: For Biotest it’s 89 employees (Europe) and 1,029 for Grifols (global). Total: 1,118. The breakdown for Grifols regarding region and employee category is as follows: Administratives/Manufacturing: 13 in Europe, 10 in USA and 9 in the rest of the world. Directors: 31 in Europe, 67 in USA and 10 in the rest of the world. Executives: 9 in Europe, 7 in USA and 1 in the rest of the world. Management: 107 in Europe, 43 in USA and 29 in the rest of the world. Professional: 142 in Europe, 15 in USA and 34 in the rest of the world. Senior management: 80 in Europe, 57 in USA and 19 in the rest of the world. Senior Professional: 87 in Europe, 226 in USA and 33 in the rest of the world.</p> <p>Grifols’ employees most likely to witness cases of corruption have undergone specific training on anticorruption in 2023: For Biotest it’s 85 employees (Europe) and 990 in Grifols (global). Total: 1,075. The breakdown for Grifols regarding region and employee category is as follows: Administratives/Manufacturing: 10 in Europe, 9 in USA and 8 in the rest of the world. Directors: 31 in Europe, 61 in USA and 10 in the rest of the world. Executives: 9 in Europe, 7 en in USA and 1 in the rest of the world. Management: 104 in Europe, 40 in USA and 29 in the rest of the world. Professional: 136 in Europe, 15 in USA and 34 in the rest of the world. Senior management: 80 in Europe, 54 in USA and 19 in the rest of the world. Senior Professional: 85 in Europe, 216 in USA and 32 in the rest of the world.”</p>	No information available related to the requirements c

GRI Standards	GRI Disclosure		Page number, URL and/or direct response	Omission
GRI 205: Anti-corruption 2016	205-3	Confirmed incidents of corruption and actions taken	226-227, 232	
GRI 207: Tax 2019	207-1	Approach to tax	261-264	
	207-2	Tax governance, control, and risk management	262-264	
	207-3	Stakeholder engagement and management of concerns related to tax	262-264	
	207-4	Country-by-country reporting	172, 267	No information available related to the requirements b-i, b-ii, b-iv, b-v, b-vii, b-ix, b-x. Breakdown of country-by-country information is not available for publication in this report.
GRI 415 Public Policy (2016)	415 -1	Political contributions	230	
GRI 417 Marketing and Labeling	417-3	Incidents of non-compliance concerning marketing communications	50	
Health contribution (patients and society)				
GRI 3: Material Topics 2021	3 - 3	Management of material topics	63-71, 221	No information available related to the requirements a, b, d, e, f
Employee commitment				
GRI 3: Material Topics 2021	3 - 3	Management of material topics	134-137, 221	No information available related to the requirements a, b, d, e, f
GRI 401: Employment 2016	401-1	New employee hires and employee turnover	<p>New hires by region: United States: 5,168 employees, rate 37.13% Europe: 970 employees, rate 14.52% Rest of the world: 108 employees, rate 19.85%</p> <p>New hires by age group: <30: 3,521 employees, rate 61.75% 30-50: 2,318 employees, rate 21.21% >50: 407 employees, rate 9.02%</p> <p>Total number of departures and staff turnover rate by region: United States: 7,800 employees, rate 56.04% Europe: 997 employees, rate 14.92% Rest of the world: 97 employees, rate 17.83%</p> <p>Total number of departures and staff turnover rate by age group: <30: 3,946 employees, rate 69.2% 30-50: 3,800 employees, rate 34.76% >50: 1,148 employees, rate 25.45%</p>	
	401-2	Benefits provided to full-time employees that are not provided to temporary or part-time employees	All employees of the main locations with the exception of the US receive the same benefits and labor benefits according to their category regardless of the type of contract (full or part time). In the US, all full-time workers who work an average of 30 hours or more a week, as well as their partner and children, have various insurance policies (Life insurance, group accident insurance, short-term work disability insurance), term and long-term and work-related travel accident insurance). They also participate in the Employee Assistance Program, a health and wellness program (LiveWell Wellness Incentive Program and Gympass), 401k Match, reimbursement for training, vacation pay (PTO Pay, Holiday Pay) and have adoption assistance. Part-time workers receive 401k, work-related travel accident insurance, participate in the Employee Assistance Program and the LiveWell Wellness Incentive Program and Gympass.	
	401-3	Parental leave	184	
GRI 402: Labor/management relations	402-1	Minimum notice periods regarding operational changes	Significant operational changes in the organization that may substantially affect employees are notified with the minimum notice established in compliance with applicable legislation and collective bargaining agreements.	
GRI 405: Diversity and Equal Opportunity 2016	405-1	Diversity of governance bodies and employees	215-216, 172-177	
	405-2	Ratio of basic salary and remuneration of women to men	189-190	
GRI 406: Non-discrimination 2016	406-1	Incidents of discrimination and corrective actions taken	142	

GRI Standards		GRI Disclosure	Page number, URL and/or direct response	Omission
GRI 403: Occupational Health and Safety 2018	403-1	Occupational health and safety management system	162-163, 165	
	403-3	Occupational health services	162-163, 165	
	403-4	Worker participation, consultation, and communication on occupational health and safety	160	
	403-5	Worker training on occupational health and safety	162-163	
	403-6	Promotion of worker health	162-164	
	403-7	Prevention and mitigation of occupational health and safety impacts directly linked by business relationships	162-163	
	403-9	Work-related injuries	165, 185	No information available related to the requirements b-i, b-ii, b-iv, b-v.
	403-10	Occupational diseases	165, 185	No information available related to the requirements b.
Data protection and cybersecurity				
GRI 3: Material Topics 2021	3 - 3	Management of material topics	221-224	No information available related to the requirements a, b, d, e, f
GRI 418: Customer Privacy 2016	418-1	Substantiated complaints concerning breaches of customer privacy and losses of customer data	222	
Innovation and knowledge generation				
GRI 3: Material Topics 2021	3 - 3	Management of material topics	73, 75-77, 80-81, 83, 86, 89, 150-151, 221	No information available related to the requirements a, b, d, e, f
GRI 404: Training and education 2016	404-1	Average hours of training per year per employee	Average hours of training per employee by gender: Women 347.54 hours and Men 210.04 hours. By professional category: Executives: 16.2h Directors: 33.73h Senior Management: 42.41h Management: 53.15h Senior Professional: 58.83h Professional: 133.17h Administrative/Manufacturing operators: 401.47h Average hours of training per employee calculated from the cumulative average workforce for the year (FTE average)	
	404-2	Programs for upgrading employee skills and transition assistance programs	148-149,153	
	404-3	Percentage of employees receiving regular performance and career development reviews	184	
Contribution to society				
GRI 3: Material Topics 2021	3 - 3	Management of material topics	194-197,221	No information available related to the requirements a, b, d, e, f
GRI 203: Indirect Economic Impacts 2016	203-1	Infrastructure investments and services supported	195-201	
Product safety and quality				
GRI 3: Material Topics 2021	3 - 3	Management of material topics	46-50, 221	No information available related to the requirements a, b, d, e, f
GRI 416: Customer Health and Safety 2016	416-1	Assessment of the health and safety impacts of product and service categories	46-51	
	416-2	Incidents of non-compliance concerning the health and safety impacts of products and services	47-50	
Plasma and donors				
GRI 3: Material Topics 2021	3 - 3	Management of material topics	53, 55, 60, 221 Coverage: Within and outside of the organization. The organization contributes directly to the impact.	No information available related to the requirements a, b, d, e, f

Annex VIII.

SASB Content Index




Sustainability Accounting Standards Board (SASB) - Biotechnology & Pharmaceuticals		
SASB Indicator	Accounting metric	Disclosure and/or references
Safety of Clinical Trial Participants		
		76-77, 224
HC-BP-210a.1	Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials	For more information please visit: https://www.clinicaltrialsregister.eu/ctr-search/search/ https://www.clinicaltrials.gov/ https://eudract.ema.europa.eu/
HC-BP-210a.2	Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)	Grifols has not received any FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in VAI or OAI. Portfolio available at www.grifols.com
HC-BP-210a.3	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	There has not been any monetary loss as a result of legal proceedings associated with clinical trials in developing countries
Access to Medicines		
HC-BP-240a.1	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	65-67
HC-BP-240a.2	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	Grifols has no products on the WHO List of Prequalified Medicinal Products.
Affordability & Pricing		
HC-BP-240b.1	Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period	Grifols does not market generic products.
HC-BP-240b.2	Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year	This information is not reported regarding confidentiality issues
HC-BP-240b.3	Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year	This information is not reported regarding confidentiality issues
Drug Safety		
HC-BP-250a.1	List of products listed in the Food and Drug Administration's (FDA) MedWatch Safety Alerts for Human Medical Products database	Information available on the FDA Safety Information and Adverse Event Reporting Program website: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
HC-BP-250a.2	Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System	Information available on the FDA Adverse Event Reporting System (FAERS) Public Dashboard: https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard
HC-BP-250a.3	Number of recalls issued, total units recalled	47
HC-BP-250a.4	Total amount of product accepted for takeback, reuse, or disposal	We do not accept the return of products for reuse. We collect the products for disposal in accordance with the legal requirements of each country
HC-BP-250a.5	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	Grifols has not received any FDA enforcement action associated with warning letters, seizures, recalls or consent decrees in 2021.
Counterfeit Drugs		
HC-BP-260a.1	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	49
HC-BP-260a.2	Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products	49
HC-BP-260a.3	Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products	49

Sustainability Accounting Standards Board (SASB) - Biotechnology & Pharmaceuticals		
SASB Indicator	Accounting metric	Disclosure and/or references
Ethical Marketing		
HC-BP-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	50
HC-BP-270a.2	Description of code of ethics governing promotion of off-label use of products	50
Employee Recruitment, Development & Retention		
HC-BP-330a.1	Discussion of talent recruitment and retention efforts for scientists and research and development personnel	148-149
HC-BP-330a.2	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others	178
Supply Chain Management		
HC-BP-430a.1	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third party audit programs for integrity of supply chain and ingredients	Grifols does not have facilities that participate in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent programs. However, our facilities are frequently audited by the respective Health authorities of the countries in which we distribute our products. Our suppliers are audited by our own teams of auditors that ensure compliance with all the requirements requested by the health authorities.
Business Ethics		
HC-BP-510a.1	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	226
HC-BP-510a.2	Description of code of ethics governing interactions with health care professionals	228-229
Activity metrics		
HC-BP-000.A	Number of patients treated	53, 64
HC-BP-000.B	Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)	12-13, 78, 80, 82, 84 portfolio available at www.grifols.com






Annex IX.

Index of the SDGs and principles of the United Nations Global Compact to which Grifols contributes

This index collects the main SDGs and principles of the United Nations Global Compact to which Grifols contributes with its activity. The main areas of Grifols' contributions include references to indicate where additional information can be found in the 2023 Integrated Annual Report.



SDG	Targets	Block within the Integrated Annual Report	Chapter within the Integrated Annual Report	Section within the Integrated Annual Report	Detailed information on the contribution	Related United Nations Global Compact Principles					
 <p>SDG 3 Good health and well-being</p>	3.3. End the epidemics of AIDS, tuberculosis, malaria, and neglected tropical diseases and combat hepatitis, water-borne diseases, and other communicable diseases.	1. Understanding Grifols	Sustainability and Human rights, p. 18-35			<ul style="list-style-type: none"> Principle 1. We support and respect the protection of internationally proclaimed human rights in our areas of influence. Principle 2. We do everything possible to ensure our operations are not complicit in human rights abuses. 					
	3.4. Reduce pre-mature mortality from non-communicable diseases (NCDs) by one-third through prevention and treatment and promote mental health and wellbeing.						Grifols' value chain, p. 36-51			<ul style="list-style-type: none"> Principle 2. We do everything possible to ensure our operations are not complicit in human rights abuses. 	
							Donors and patients, p. 52-71				
							Innovation at Grifols	Treatment innovations	<ul style="list-style-type: none"> Maximizing Biotest's full potential, p. 79 We promote wide-ranging in-house initiatives, p. 80 Milestones and advances in plasma therapies, p. 81 Other initiatives in neurodegenerative diseases, p. 82 GigaGen, non-plasma innovations, p. 83 		
			Innovation in Diagnostics	<ul style="list-style-type: none"> Milestones and product launches, p. 84-85 							
 <p>SDG 8 Decent work and economic growth</p>	8.5. Provide decent work for all women and men, including young people and persons with disabilities through full and productive employment with equal pay.	2. ESG	Social: Grifols' greatest asset	We grow alongside our team	<ul style="list-style-type: none"> We grow alongside our team, p. 138 Diversity and inclusion, p. 140 Anti-discrimination principles and actions, p. 142 Integrating people with disabilities, p. 143 Equal opportunity plans, p. 144 A holistic understanding of equality, p. 144 Women in Grifols, p. 145 	<ul style="list-style-type: none"> Principle 3. We uphold the freedom of association and the effective recognition of the right to collective bargaining. Principle 4. We support the elimination of all forms of forced and compulsory labor. Principle 5. We support the effective abolition of all forms of child labor. Principle 6. We support the elimination of discrimination in respect of employment and occupation. 					
								Fair compensation practices	<ul style="list-style-type: none"> Remuneration system, p. 155 Moving towards pay equity, p. 156-157 Grifols continues to make progress towards parity, p. 158-159 	<ul style="list-style-type: none"> Principle 6. We support the elimination of discrimination in respect of employment and occupation. 	
							3. Sustainable growth	Grifols' value creation, p. 257-260			
	8.8. Protect labor rights and promote safe and secure working environments for all workers.						2. ESG	Social: Grifols' greatest asset	Occupational health and well-being	<ul style="list-style-type: none"> Mental Health Policy, leading by example, p. 162 Integrated health and safety management, p. 163 Promoting our employees' health and well-being, p. 164 Performance in occupational health and safety, p. 165 Absenteeism, p.165 Work-life balance, p. 166 	<ul style="list-style-type: none"> Principle 3. We uphold the freedom of association and the effective recognition of the right to collective bargaining. Principle 4. We support the elimination of all forms of forced and compulsory labor.
 <p>SDG 9 Industry, innovation and infrastructure</p>	9.4. Upgrade infrastructure and retrofit industries to make them sustainable and with increased resources use efficiency and greater adoption of clean and environmentally sound technologies and industrial processes.	1. Understanding Grifols	Donors and patients	Access to treatment and diagnosis	<p>Program to promote countries' self-sufficiency in plasma and plasma-derived medicines: leading the change, p. 65-67</p>						
							Innovation at Grifols	A robust innovation system, p. 73			
								New leadership, p. 74			
								Digital innovation, p. 86-87			
	9.5 Enhance scientific research, upgrade the technological capabilities of industrial sectors in all countries, including encouraging innovation and substantially increasing the number of research and development workers and public and private research and development spending.	1. Understanding Grifols	Innovation at Grifols	Resources allocated to R&D+i, p. 75	<ul style="list-style-type: none"> Our commitments, p. 77 						
			Ethics science and innovation		<ul style="list-style-type: none"> Sponsorship of ISR Program, p. 89 Grifols Chair for the study of Chirrosis and Albumin, p. 89 Grifols Scientific Awards and research grants, p. 89 Scientific journal specialized in plasma, p. 89 						
			Research collaborations and support								

Priority objectives

SDG	Targets	Block within the Integrated Annual Report	Chapter within the Integrated Annual Report	Section within the Integrated Annual Report	Detailed information on the contribution	Related United Nations Global Compact Principles
 <p>SDG 12 Responsible consumption and production</p>	12.2. Achieve sustainable management and efficient use of natural resources.	2. ESG	Environmental	Environmental management at Grifols	<ul style="list-style-type: none"> A cross-cutting and comprehensive approach, p. 93 	<ul style="list-style-type: none"> Principle 7. We support a precautionary approach to environmental challenges. Principle 8. We undertake initiatives to promote greater environmental responsibility. Principle 9. We encourage the development and diffusion of environmentally friendly technologies.
				<ul style="list-style-type: none"> A continually evolving internal regulatory system Environmental governance and climate change action, p. 96 A global organization to manage environmental risks, p. 97 Resources allocated to environmental management and climate change, p. 98 2023-2026 Environmental Program, p. 99-100 Energy sources: responsible consumption <ul style="list-style-type: none"> Natural gas, p.106 Electricity, p. 107 Renewable energies, p. 108 Circular economy <ul style="list-style-type: none"> Consumption of raw materials, p. 111 Water cycle, p. 112-113 		
 <p>SDG 13 Climate action</p>	12.5. Substantially reduce waste generation through prevention, reduction, recycling, and reuse.	2. ESG	Environmental	Circular economy, p. 110-111 Waste, p. 114-115		<ul style="list-style-type: none"> Principle 7. We support a precautionary approach to environmental challenges. Principle 8. We undertake initiatives to promote greater environmental responsibility. Principle 9. We encourage the development and diffusion of environmentally friendly technologies.
	13.1. Strengthen resilience and adaptive capacity to climate-related hazards and natural disasters in all countries.	1. Understanding Grifols	Sustainability and Human rights	Sustainability as a roadmap	<ul style="list-style-type: none"> Materiality, p. 20-25 	
 <p>SDG 4 Quality education</p>		2. ESG	Environmental	Climate action	<ul style="list-style-type: none"> The impact of climate change on Grifols, p. 101-102 Emissions, p. 103-104 	<ul style="list-style-type: none"> Principle 3. We uphold the freedom of association and the effective recognition of the right to collective bargaining. Principle 4. We support the elimination of all forms of forced and compulsory labor. Principle 5. We support the effective abolition of all forms of child labor. Principle 6. We support the elimination of discrimination in respect of employment and occupation.
	4.3. Ensure equal access for all women and men to affordable and quality technical, vocational, and tertiary education.		Social: Grifols' greatest asset	Talent development	<ul style="list-style-type: none"> Talent development, p.146 Grifols Performance System, p. 147 People development programs, p. 148 Attracting new talent, p. 149 Student internships, p. 149 	
				Driving continuous development	<ul style="list-style-type: none"> Our culture of learning in 2023, p. 150 Employee development innovations, p. 151 Overview of Grifols employee development, p. 152 	
	4.5. Eliminate gender disparities in education by ensuring equal access to all levels of educational and vocational training for the vulnerable, including persons with disabilities, indigenous peoples, and children in vulnerable situations.	2. ESG	Social: Community investment and social outreach	Social action	<ul style="list-style-type: none"> Health and well-being, p. 198 Education, p. 200 Initiatives through foundations and NGOs <ul style="list-style-type: none"> Probitas Foundation: improving the health of the most vulnerable populations, p. 203-205 Victor Grifols Lucas Foundation: bioethics as a principle, p. 206-208 José Antonio Grifols Lucas Foundation: supporting donor communities, p. 209-211 	
 <p>SDG 5 Gender equality</p>	5.1. End all forms of discrimination against women and girls everywhere.	2. ESG	Social: Grifols' greatest asset	We grow alongside our team	<ul style="list-style-type: none"> Diversity and inclusion, p. 140-141 Anti-discrimination principles and actions, p. 142 Equal opportunity plans, p. 144 A holistic understanding of equality, p. 144 Women in Grifols, p. 145 	<ul style="list-style-type: none"> Principle 3. We uphold the freedom of association and the effective recognition of the right to collective bargaining. Principle 4. We support the elimination of all forms of forced and compulsory labor. Principle 5. We support the effective abolition of all forms of child labor. Principle 6. We support the elimination of discrimination in respect of employment and occupation.
	5.5. Ensure equal opportunities for leadership and full and effective participation for women at all levels of decision-making in political, economic, and public life.			Fair compensation practices	<ul style="list-style-type: none"> Remuneration system, p. 155 Moving towards pay equity, p. 156-157 Grifols continues to make progress towards parity, p. 158-159 	
			Social: Community investment and social outreach	Social action	<ul style="list-style-type: none"> Sponsorships: Supporting women in sport, p. 202 	
 <p>SDG 10 Reduced inequalities</p>	10.2. Empower and promote the social, economic and political inclusion of all irrespective of age, sex, disability, race, ethnicity, origin, religion or economic or other status.	1. Understanding Grifols	Donors and patients	Serving as a bridge between donors and patients, p. 53 Donation centers in committed communities, p. 62 Access to treatment and diagnosis, p. 65-68 Patient associations, p. 69-71		<ul style="list-style-type: none"> Principle 6. We support the elimination of discrimination in respect of employment and occupation.
		2. ESG	Social: Helping create more sustainable health systems	The value of our collaboration, p. 191 Optimizing health costs, p. 192 Collaborations with blood banks, p. 193		
			Social: Community investment and social outreach	Principles, our stakeholder groups and scope, p. 194 Total contributions in 2023, p. 195 Social action, p. 196-201		
				Initiatives through foundations and NGOs	<ul style="list-style-type: none"> Probitas Foundation: improving the health of the most vulnerable populations, p. 203-205 Victor Grifols Lucas Foundation: bioethics as a principle, p. 206-208 José Antonio Grifols Lucas Foundation: supporting donor communities, p. 209-211 	

Priority objectives

Relevant objectives

SDG	Targets	Block within the Integrated Annual Report	Chapter within the Integrated Annual Report	Section within the Integrated Annual Report	Detailed information on the contribution	Related United Nations Global Compact Principles	
Relevant objectives	 <p>SDG 16 Peace, justice and strong institutions</p>	16.5 Substantially reduce corruption and bribery in all its forms.	2. ESG	Governance	We promote integrity · Integrated anti-corruption model, p. 226-227 Grifols Ethics Line, p. 232	· Principle 10. We work against corruption in all its forms, including extortion and bribery.	
		16.10 Ensure public access to information and protect fundamental freedoms, in accordance with national legislation and international agreements.	1. Understanding Grifols 2. ESG	Sustainability and Human rights Governance	Human rights: an essential pillar, p. 32-35 We are transparent, p. 228-231	· Principle 10. We work against corruption in all its forms, including extortion and bribery.	
Cross-cutting objectives	 <p>SDG 17 Partnerships for the goals</p>	17.6 Enhance North-South, South-South and triangular regional and international cooperation on and access to science, technology and innovation, and enhance knowledge sharing on mutually agreed terms, including through improved coordination among existing mechanisms, particularly at UN level, and through a global technology facilitation mechanism when agreed.	1. Understanding Grifols 2. ESG	Donors and patients Social: Helping create more sustainable health systems Social: Community investment and social outreach	Access to treatment and diagnosis Program to promote countries' self-sufficiency in plasma and plasma-derived medicines: leading the change, p. 65-67 The value of our collaboration, p. 191 Optimizing health costs, p. 192 Collaborations with blood banks, p. 193 Initiatives through foundations and NGOs · Probitas Foundation: improving the health of the most vulnerable populations, p. 203-205 · Victor Grifols Lucas Foundation: bioethics as a principle, p. 206-208 · José Antonio Grifols Lucas Foundation: supporting donor communities, p. 209-211		
		17.16 Enhance the global partnership for sustainable development, complemented by multi-stakeholder partnerships that mobilize and share knowledge, expertise, technology and financial resources, to support the achievement of the sustainable development goals in all countries, in particular developing countries.	1. Understanding Grifols 2. ESG	Innovation at Grifols Social: Grifols' greatest asset	Treatment innovations Digital innovation, p. 86-87 Research collaborations and support Driving continuous development	· Maximizing Biotest's full potential, p. 79 · We promote wide-ranging in-house initiatives, p. 80 · Milestones and advances in plasma therapies, p. 81 · Other initiatives in neurodegenerative diseases, p. 82 · GigaGen, non-plasma innovations, p. 83 · Sponsorship of ISR Program, p. 89 · Grifols Chair for the study of Chirrosis and Albumin, p. 89 · Grifols Scientific Awards and research grants, p. 89 · Scientific journal specialized in plasma, p. 89 · Overview of Grifols employee development 2023, p. 152 · Training programs, p. 153 · Grifols Academy: differential learning opportunities, p. 154	
		17.17 Encourage and promote effective public, public-private and civil society partnerships, building on the experience and resourcing strategies of partnerships.	2. ESG	Environmental Social: Helping create more sustainable health systems Social: Community investment and social outreach	Waste Biodiversity, p. 116-118 The value of our collaboration, p. 191 Optimizing health costs, p. 192 Collaborations with blood banks, p. 193 Social action	· Medicine waste management, p. 115 · Environmental, p. 201	

Annex X

NON-GAAP measures reconciliation

FY 2023 - NET REVENUE RECONCILIATION CONSTANT CURRENCY

In thousands of euros	2023	2022	% Var
Reported Net Revenues	6,591,977	6,063,967	8.7%
Variation due to Exchange Rate Effects	133,610		
Net Revenues at Constant Currency	6,725,587	6,063,967	10.9%

In thousands of euros	2023	2022	% Var
Reported Biopharma Net Revenues	5,558,301	5,005,382	11.0%
Variation due to Exchange Rate Effects	112,083		
Reported Biopharma Net Revenues at Constant Currency	5,670,384	5,005,382	13.3%

In thousands of euros	2023	2022	% Var
Reported Diagnostic Net Revenues	670,269	671,292	(0.2%)
Variation due to Exchange Rate Effects	16,517		
Reported Diagnostic Net Revenues at Constant Currency	686,786	671,292	2.3%

In thousands of euros	2023	2022	% Var
Reported Bio Supplies Net Revenues	159,957	146,076	9.5%
Variation due to Exchange Rate Effects	2,655		
Reported Bio Supplies Net Revenues at Constant Currency	162,612	146,076	11.3%

In thousands of euros	2023	2022	% Var
Reported Others & Intersegments Net Revenues	203,450	241,217	(15.7%)
Variation due to Exchange Rate Effects	2,354		
Reported Other & Intersegments Net Revenues at Constant Currency	205,804	241,217	(14.7%)

In thousands of euros	2023	2022	% Var
Reported U.S. + Canada Net Revenues	3,898,961	3,855,607	1.1%
Variation due to Exchange Rate Effects	88,993		
Reported U.S. + Canada Net Revenues at Constant Currency	3,987,954	3,855,607	3.4%

In thousands of euros	2023	2022	% Var
Reported EU Net Revenues	1,255,927	1,032,211	21.7%
Variation due to Exchange Rate Effects	749		
Reported EU Net Revenues at Constant Currency	1,256,676	1,032,211	21.7%

In thousands of euros	2023	2022	% Var
Reported ROW Net Revenues	1,437,089	1,176,149	22.2%
Variation due to Exchange Rate Effects	43,868		
Reported ROW Net Revenues at Constant Currency	1,480,957	1,176,149	25.9%

FY 2023 - NET REVENUE RECONCILIATION CONSTANT CURRENCY EXCLUDING BIOTEST

In thousands of euros	2023	2022	% Var
Reported Net Revenues	6,088,891	5,702,728	6.8%
Variation due to Exchange Rate Effects	133,233		
Net Revenues at Constant Currency	6,222,124	5,702,728	9.1%

In thousands of euros	2023	2022	% Var
Reported Biopharma Revenues	5,055,215	4,644,143	8.9%
Variation due to Exchange Rate Effects	111,706		
Reported Biopharma Net Revenues at Constant Currency	5,166,921	4,644,143	11.3%

In thousands of euros	2023	2022	% Var
Reported U.S. + Canada Net Revenues	3,897,511	3,853,488	1.1%
Variation due to Exchange Rate Effects	88,993		
Reported U.S. + Canada Net Revenues at Constant Currency	3,986,504	3,853,488	3.5%

In thousands of euros	2023	2022	% Var
Reported EU Net Revenues	990,925	851,795	16.3%
Variation due to Exchange Rate Effects	969		
Reported EU Net Revenues at Constant Currency	991,894	851,795	16.4%

In thousands of euros	2023	2022	% Var
Reported ROW Net Revenues	1,200,455	997,445	20.4%
Variation due to Exchange Rate Effects	43,271		
Reported ROW Net Revenues at Constant Currency	1,243,726	997,445	24.7%

FY 2023 - OTHER RECONCILIATIONS INCLUDING BIOTEST

In thousands of euros	2023	2022	% Var
Net Financial Debt	9,416,312	9,191,000	2.5%
EBITDA Adjusted 12M	1,484,650	1,287,000	
Net Leverage Ratio ¹	6,3x	7,1x	(11.1%)

(1) Excludes the impact of IFRS 16

In thousands of euros	2023	2022	% Var
EBIT	799,398	805,680	(0.8%)
D&A	451,759	415,339	
EBITDA Reported	1,251,157	1,221,019	2.5%

In thousands of euros	2023	2022	% Var
EBIT	799,398	805,680	(0.8%)
D&A	451,757	415,339	
Non-recurring costs ²	223,009	25,866	
EBITDA Adjusted	1,474,164	1,246,885	18.2%

(2) Includes restructuring, divestment and transaction costs

In thousands of euros	2023	2022	% Var
EBIT	799,398	805,680	(0.8%)
D&A	451,757	415,339	
IFRS 16	-101,784	-99,990	
Non-recurring Items ³	335,276	166,174	
EBITDA Covenant	1,484,650	1,287,203	15.3%

(3) Non-recurring items are mainly related to transaction, restructuring and divestitures costs, as well as the amount of cost savings, operating improvements and synergies on a "run rate"

In thousands of euros	2023	2022	% Var
R&D recurrent expenses in P&L	395.3	361.1	9.5%
R&D capitalized	51.4	36.0	42.9%
R&D depreciation, amortization and write-offs	(64.7)	(43.9)	47.5%
R&D CAPEX fixed assets	2.1	0.9	138.0%
R&D external	(1.9)	(2.8)	(31.9%)
R&D net investment	382.2	351.3	8.8%

In thousands of euros	2023	2022	% Var
PP&E additions	246,430	291,676	(15.5%)
Interest capitalized	(36,862)	(25,184)	46.4%
CAPEX	209,568	266,492	(21.4%)

Note: for comparison purposes, figure reported in 2022 (EUR 297m) differs following a change of criteria in 2023 as software is not considered CAPEX anymore

Annex XI.

Glossary and abbreviations

- **Alpha-1 antitrypsin deficiency (AATD):** inherited disease characterized by low levels or no alpha-1 antitrypsin (AAT) in the bloodstream. In its normal function, this protein is generated in the liver, released in the bloodstream and diffused to other organs such as the lungs.
- **Albumin:** the most abundant protein found in plasma (approximately 60% of human plasma). Produced in the liver, it is important in regulating blood volume by maintaining the oncotic pressure of the blood compartment.
- **Alzheimer's disease (AD):** the most common form of dementia, AD is an incurable, degenerative and terminal disease first described in 1906 by German psychiatrist and neuropathologist Alois Alzheimer.
- **Anti-thymocyte globulin (ATG):** blood serum with antibodies that bind with human T-cells, administered to patients before a stem cell transplant to destroy T-cells and decrease the risk of graft-versus-host disease.
- **ASFA:** American Society for Apheresis, an organization of physicians, scientists and allied health professionals dedicated to promoting apheresis medicine for patients, donors and professionals through education, evidence-based practice, research and advocacy.
- **Autoimmune disease:** condition in which the immune system mistakenly attacks healthy cells.
- **Babesiosis/Babesia virus:** disease caused by microscopic parasites that infect red blood cells.
- **Beta-amyloid:** protein strongly implicated in Alzheimer's diseases as the main component of certain deposits found in the brains of AD patients.
- **Bullous pemphigoid:** autoimmune disease that appears when the immune system attacks the skin and causes blisters, more common among the elderly.
- **CIDP (chronic inflammatory demyelinating polyneuropathy):** neurological disorder which causes gradual weakness, numbness, pain in the arms and legs, and difficulty in walking.
- **Cirrhosis:** medical condition resulting from advanced liver disease, characterized by generation of liver tissue by fibrosis (scar tissue) and regenerative nodules (lumps that occur due to attempted repair of damaged tissue).
- **Cognitive impairment:** alterations in thinking, learning, memory, judgment and decision making.
- **COVID-19:** infectious disease caused by a new coronavirus strain, with "CO" short for corona, "VI" for virus and "D" for disease.
- **ELISA:** enzyme-linked immunosorbent assay.
- **EMA:** European Medicines Agency
- **Factor VIII or FVIII:** an essential blood clotting factor also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene. Defects in this gene lead to hemophilia A, a sex-linked disease occurring predominantly in males. FVIII concentrated from donated blood plasma or recombinant FVIII (rFVIII) can be administered to hemophiliacs to restore hemostasis.
- **Factor IX:** an important blood clotting factor also known as Christmas factor or plasma thromboplastin component (PTC). It is one of the serine proteases of the coagulation system belonging to the peptidase family S1. In humans, a deficiency of this protein causes hemophilia B, a sex-linked disease that occurs predominantly in males.
- **FDA:** Food and Drug Administration, a U.S. health authority.
- **Fibrin sealant:** surgical adhesive material derived from plasma.
- **Fibrinogen:** coagulation factor found in human plasma crucial for blood clot formation.
- **Fractionation:** process of separating plasma into its component parts including albumin, immunoglobulin, alpha-1 antitrypsin and coagulation factors.
- **GMP:** good manufacturing practice.
- **GPO:** group purchasing organization.
- **HAE (hereditary angioedema):** Rare but serious genetic disorder characterized by recurrent episodes of severe swelling (angioedema), particularly of the face and airways, and abdominal cramping, caused by low levels or improper function of the C1- esterase inhibitor protein.
- **HBV:** hepatitis B virus.
- **HCV:** hepatitis C virus.
- **Hematocrit:** the percentage of red blood cells in the blood.
- **Hematology:** the study of blood, blood-forming organs and blood diseases.
- **Hemoderivative:** proteins obtained from the fractionation of human blood plasma (see plasma-derived proteins).
- **Hemophilia:** genetic deficiency characterized by the lack of one of the clotting factors, with two main variants:
 - **Hemophilia A:** genetic deficiency of coagulation Factor VIII, which causes increased bleeding (more prevalent among males).
 - **Hemophilia B:** genetic deficiency of coagulation Factor IX.
- **Hemotherapy:** treatment of a disease using blood, blood components and its derivatives.
- **HIV:** human immunodeficiency virus.
- **Hyperimmune globulins:** type of immunoglobulins prepared in a manner similar to human normal immunoglobulin, except that the donor plasma has high titers of antibodies against an organism or antigen.

- **IA:** immunoassays, systems available in several formats to detect antibodies, recombinant proteins or a combination thereof.
- **Intravenous:** administration of drugs or fluids directly into a vein.
- **Immunohematology:** branch of hematology related to the study of recombinant proteins and antibodies and their effects on blood and relationships between blood disorders and the immune system. Also referred to as transfusion medicine – blood bank, its main activities include blood typing, compatibility tests and crossmatching and antibody identification.
- **Immunology:** branch of biomedical science that covers the study of all aspects of the immune system in organisms, encompassing the physiological functioning of the immune system in states of both health and disease; malfunctions (autoimmune diseases, hypersensitivities, immune deficiency, transplant rejection) and the physical, chemical and physiological characteristics of the components of the immune system in vitro, in situ and in vivo.
- **Immunoglobulin (IgG):** plasma-derived proteins also known as antibodies that control the body's immune response. They have multiple indications, with main uses including the treatment of: (i) immune deficiencies, (ii) inflammatory and autoimmune diseases and (iii) acute infections. IVIG is an immunoglobulin administered intravenously that contains IgG (immunoglobulin (antibody) G).
- **ITP (chronic immune thrombocytopenia):** autoimmune disorder in which patients produce antiplatelet autoantibodies and specialized white blood cells that destroy their blood platelets. This results in a low blood platelet count (thrombocytopenia) that may produce bruising or excessive bleeding.
- **IVD:** in vitro diagnostic.
- **IV solutions/intravenous solution:** medicine or homogeneous mixture of a substance in liquid, enabling its infusion into the circulatory system through a needle.
- **Lipemic plasma:** plasma with a cloudy and/or milky appearance caused by excess lipids (hyperlipidemia) due mainly to cholesterol and/or triglycerides in the blood.
- **MRB:** Marketing Research Bureau.
- **Molecular diagnostic:** discipline that studies genomic (DNA) and proteomic (proteins) expression patterns using information to distinguish between normal, precancerous and cancerous tissues at the molecular level.
- **Monoclonal antibody (mAb):** antibody produced by a single clone of cells typically used in immunotherapy (i.e. treatments of autoimmune or inflammatory disorders and cancer); diagnostic testing; cell identification; and tracking. Monoclonal antibodies are a cornerstone of immunology and becoming increasingly prevalent as therapeutic agents.
- **Myasthenia gravis (MG):** chronic autoimmune, neuromuscular disease that causes weakness in the skeletal muscles which worsens after periods of activity and improves after periods of rest. These muscles are responsible for functions involving breathing and moving parts of the body.
- **NAT:** nucleic acid amplification testing.
- **Neurology:** science that deals with the anatomy, functions and organic disorders of nerves and the nervous system.
- **North America:** United States and Canada.
- **Ophthalmology:** branch of medicine and surgery that deals with the diagnosis and treatment of eye diseases.
- **Pandemic:** worldwide spread of a new disease.
- **Parkinson's disease:** complex neurodegenerative disorder characterized by different combinations of motor and non-motor symptoms for each patient.
- **PCR:** polymerase chain reaction, a method widely used to rapidly make millions to billions of copies of a specific DNA sample, allowing scientists to take a very small sample of DNA and amplify it to a large enough amount to study in detail.
- **pdFVIII:** plasma-derived Factor VIII.
- **Pharmacovigilance:** practice of monitoring the effects of medical drugs after they have been licensed for use, especially to identify and evaluate previously unreported adverse reactions
- **Plasma:** yellow-hued liquid part of the blood comprised by numerous proteins in solution.
- **Plasma-derived proteins:** purified plasma proteins with therapeutic properties obtained through the fractionation of human plasma. Albumin, immunoglobulins, factor VIII and alpha-1 antitrypsin are the main plasma proteins.
- **Plasma proteomic:** high-throughput analysis of plasma biomarkers using very powerful and sensitive specialty instruments.
- **Plasmapheresis:** technique by which plasma is separated from other blood components such as red blood cells, platelets and other cells. These unused blood components are suspended in saline solution and immediately reinjected back into the donor. Since donors only provide plasma as opposed to whole blood, the recovery process is faster and better tolerated, enabling greater frequency of donations. Developed by José Antonio Grifols Lucas in 1951, plasmapheresis is the only procedure capable of obtaining sufficient quantities of plasma to cover the manufacturing needs for plasma protein therapies.
- **Pneumology:** specialty focused on the diagnosis and treatment of respiratory diseases and conditions, from asthma to tuberculosis.
- **PPTA:** Plasma Protein Therapeutics Association.
- **Primary arthroplasty:** surgery performed to replace damaged joints with artificial joints or prostheses, used in cases of hip fractures, osteoarthritis and other rheumatic diseases.

- **Primary immunodeficiency:** inherited condition affecting one or more areas of the immune system characterized by an impaired immune response, weakening the immune system and increasing the likelihood of infections and other health problems.
- **ProlastinR/ProlastinR-C:** concentrated form of alpha-1 antitrypsin (AAT) derived from human plasma and approved only for chronic replacement therapy in people with genetic AAT deficiency. Administered as prescribed, Prolastin raises the levels of AAT in the blood and lungs, which may help reduce the damage to the lungs caused by destructive enzymes.
- **Proteome:** complete set of proteins expressed by an organism that determine an organism's nature, bodily functioning and behavior.
- **Recombinant:** protein prepared by recombinant technology, coded by the manipulated gene, with procedures used to combine segments in a cell-free system (an environment outside a cell organism). Known as highly potent medicines, they avoid off-target side effects and take a shorter time to develop than small molecules.
- **Recovered plasma:** plasma derived from whole blood collected in blood donations.
- **rFVIII:** recombinant Factor VIII, the antihemophilic factor A obtained using recombinant DNA technology. Using this technology, pure factor is synthesized in the laboratory instead of being extracted from blood plasma.
- **Rh (Rhesus) blood group system:** the most important blood group system after ABO, the Rh blood group system consists of 50 defined blood-group recombinant proteins, among which the five recombinant proteins D, C, c, E and e are the most important. The commonly used terms Rh factor, Rh positive and Rh negative refer to the D antigen only.
- **ROW:** rest of the world.
- **SARS-CoV-2:** severe acute respiratory syndrome coronavirus 2, the coronavirus strain that causes coronavirus disease 2019 (COVID-19).
- **Secondary immunodeficiency:** compromised immune system due to an environmental factor such as HIV, chemotherapy, severe burns or malnutrition.
- **SCIG:** subcutaneous immunoglobulin.
- **Single-cell transcriptomics:** technique to characterize cell identity.
- **SubQ:** sub-cutaneous.
- **Thrombin:** enzyme that presides over the conversion of fibrinogen to fibrin, which promotes blood clotting.
- **Transfusion medicine:** branch of medicine that encompasses immunohematology, blood and plasma screening, and blood typing, among others.
- **West Nile virus (WNV):** mosquito-transmitted virus. Humans are mainly infected through mosquito bites, but infection may also occur through organ transplantation and blood.
- **Von Willebrand disease (vWD):** the most common hereditary coagulation abnormality described in humans, although it can also be acquired as a result of other medical conditions. It arises from a qualitative or quantitative deficiency of von Willebrand factor (vWF), a multimeric protein required for platelet adhesion.
- **Zika virus:** infectious disease spread by the bite of an infected Aedes species mosquito.

Independent Review Report



KPMG Asesores, S.L.
Torre Realia
Plaça d'Europa, 41-43
08908 L'Hospitalet de Llobregat
Barcelona

Independent Review Report on the Grifols, S.A. Annual Integrated and Sustainability Report

(Translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

To Management of Grifols, S.A.

In accordance with our engagement letter, we have performed an independent limited assurance review of the non-financial information contained in the Integrated Annual and Sustainability Report of Grifols, S.A. (hereinafter Grifols) for the year ended 31 December 2023 (hereinafter the Report).

The Report includes additional information to that required by Sustainability Reporting Standards of the Global Reporting Initiative (hereinafter GRI standards) and the Sustainability Accounting Standards Board standards (hereinafter SASB standards), which has not been the subject of our assurance work. In this respect, our work was limited exclusively to providing assurance on the information contained in "Annex VII – GRI Content Index" and "Annex VIII – SASB Content Index" of the accompanying Report.

Management's Responsibility

Grifols management is responsible for the preparation and presentation of the Report in accordance with GRI standards and SASB Standards for the Biotechnology and Pharmaceutical sector.

Moreover, management is responsible for the information and assertions contained within the Report; for determining Grifols' objectives in respect of the selection and presentation of non-financial information, including the identification of stakeholders and material topics; and for establishing and maintaining appropriate performance management and control systems from which the information is derived.

This responsibility also encompasses the design, implementation and maintenance of relevant internal control to ensure that the non-financial information contained within the Report is free from material misstatement, whether due to fraud or error.

Our Responsibility

Our responsibility is to perform a limited review and to issue this Report based on the work performed. We conducted our engagement in accordance with ISAE 3000 Assurance Engagements Other than Audits or Reviews of Historical Financial Information, issued by the International Auditing and Assurance Standards Board (IAASB). This standard requires that we plan and perform our procedures to obtain limited assurance about whether the Report is free from material misstatement.



2

(Translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

Our firm applies International Standard on Quality Management 1 (ISQM1), which requires us to design, implement and operate a system of quality management including policies or procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.

We have complied with the independence and other ethical requirements of the International Code of Ethics for Professional Accountants (including international standards on independence) issued by the International Ethics Standards Board for Accountants, which is founded on fundamental principles of integrity, objectivity, professional competence and due care, confidentiality and professional behaviour.

Procedures Performed

Our limited review work consisted of making inquiries of management and persons responsible for the preparation of the information presented in the Report, and applying analytical and other evidence gathering procedures. These procedures included:

- Evaluation of Grifols' processes for determining the material issues, and the participation of stakeholders therein.
- Interviews with relevant staff concerning sustainability strategy and policies and corporate responsibility for material issues, and the implementation of these across Grifols' business.
- Evaluation of the consistency of the description of the application of Grifols' strategy and policies on sustainability, governance, ethics and integrity.
- Risk analysis, including searching the media to identify material issues during the year covered by the Report.
- Review of the consistency of information comparing the GRI standards and SASB standards with internal systems and documentation.
- Analysis of the processes of compiling and internal control over quantitative data reflected in the Report, regarding the reliability of the information, by using analytical procedures and review testing based on sampling.
- Review of the application of the requirements of the GRI standards: "in accordance" option.
- Reading the information presented in the Report to determine whether it is in line with our overall knowledge of, and experience with, the sustainability performance of Grifols.
- Confirmation that the financial information reflected in the Report was audited by independent third parties.

Our multidisciplinary team included specialists in social, environmental and financial performance of companies.

The procedures performed in a limited assurance engagement vary in nature and timing from, and are less in extent than for a reasonable review engagement. Consequently the level of assurance obtained in a limited review engagement is lower than that of a reasonable review engagement. Under no circumstances may this Report be considered an auditor's report.



3

(Translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

Conclusion

Our conclusion has been formed on the basis of, and is subject to, the matters described in this Report. We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our conclusion.

Based on the procedures performed and the evidence obtained, nothing has come to our attention that causes us to believe that the Grifols, S.A. Annual Integrated and Sustainability Report for the year ended 31 December 2023 has not been prepared, in all material respects, in accordance with GRI standards and SASB standards for the Biotechnology and Pharmaceutical Sector, as detailed in Annex VII "GRI Content Index" and in Annex VIII "SASB Content Index" of the Report, respectively.

Purpose of our Report

In accordance with the terms of our engagement, this Independent Limited Assurance Report has been prepared for Grifols in connection with its 2023 Annual Integrated and Sustainability Report and for no other purpose or in any other context.

KPMG Asesores, S.L.

(Signed on original in Spanish)

Patricia Reverter Guillot

7 March 2024

GRIFOLS